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„Der Mensch muss bei dem Glauben verharren, dass 
das Unbegreifliche begreiflich sei; er würde sonst nicht 
forschen.“ 
 
„Humans have to hold on to the belief that the 
incomprehensible is comprehensible, otherwise they 
would not continue to explore.“ 
Johann Wolfgang von Goethe 
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1. AIM OF THE STUDY 
 
 
Rett's Syndrome (RTT) is a severe, progressive neurodevelopmental 
disorder that affects mainly females, occurring with an incidence of up to 
1:10,000 live births (Hagberg et al. 1983). After an apparently normal 
development, affected children around 6-18 months old start to display signs of 
the disease which consist in loss of speech, reduced motor abilities, respiratory 
crises, stereotyped hand movements, severe cognitive impairment and autistic 
behavior.  
 
Recent studies have shown that RTT is often linked to mutations in the 
MECP2 gene, mapped to Xq28 and encoding for methyl-CpG-binding protein 2 
(MeCP2), a methylation-dependent transcriptional repressor (Lewis et al. 1992) 
and splicing regulator (Young et al. 2005).  
 
Nonetheless a significant fraction (around 30%) of children affected by 
RTT does not carry mutation in this gene, and recent findings highlighted the fact 
that mutations in the CDKL5 (cyclin-dependent kinase-like 5) gene are 
responsible for a new disorder that in many aspects overlaps RTT but is also 
characterized by specific traits (Evans et al. 2005; Fehr et al. 2013). Mutations in 
the CDKL5 gene are associated with a severe epileptic encephalopathy 
characterized by early-onset intractable seizures, infantile spasms, severe 
developmental delay, intellectual disability, and RTT-like features.  
 
Although several distinct mutations of the CDKL5 gene have been found 
associated with the disease, the function of CDKL5 and particularly its role in 
the development of the nervous system remain totally cryptic yet, as well as it 
remains unknown how deregulated expression or mutations of CDKL5 determine 
the disease phenotype.  
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Several studies in rodents have shown that Cdkl5, a serine-threonine 
protein kinase, is highly expressed in the developing brain (Rusconi et al. 
2008; Chen et al. 2010), suggesting the importance of this kinase for proper 
brain maturation and function.  
 
Based on these premises the overall aim of the study was to characterize the 
role of CDKL5 on brain development and to identify the molecular 
mechanism/s underlying its action.  
 
In particular our aims were:  
 
i) to establish the role of CDKL5 on neuronal maturation, through an appropriate 
in vitro cellular system; 
 
ii) to generate a Cdkl5 loss of function mouse model (a Cdkl5 knockout mouse 
model);  
 
iii) using the new generated Cdkl5 knockout mouse, to dissect the role of Cdkl5 
on brain development and to identify the molecular mechanism/s underlying its 
action;  
 
This study will provide novel information on the molecular mechanism/s 
underlying brain alterations in the CDKL5 variant of RTT. This is a first and 
essential step for future studies in which the Cdkl5 knockout mouse model and the 
information gained in the current project can be exploited to devise new 
therapeutic strategies in order to improve symptoms of the CDKL5 disorder.  
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2. INTRODUCTION  
 
2.1. THE RETT’S SYNDROME 
 
2.1.1. EPIDEMIOLOGY OF RETT’S SYNDROME 
Rett’s Syndrome (RTT) [OMIM 312750] is a X-linked progressive 
neurodevelopmental disorder that affects the patient’s ability to communicate and 
perform simple motor tasks. RTT affects mainly females, occurring with an 
incidence rate of 1 up to 10,000 female live births (Hagberg et al. 1983; Neul et 
al. 2010). Although the RTT phenotype is variable, most RTT patients have a 
distinctive disease course: after a period of apparently normal development (6-18 
months) a regression appears with loss of social, motor and communication skills, 
hand stereotypies, microcephaly and mental retardation.  
Several RTT variants, that deviate from the classical clinical presentation 
and range from milder forms with a later age of onset to more severe 
manifestations, have been described. The milder forms include the preserved 
speech variant (PSV or “Zappella variant”), characterized by the recovery of some 
degree of speech and the ‘‘forme fruste” (or “worndown form”), with a milder, 
incomplete clinical course. Patients have a later age of onset compared to the 
classical form, with regression occurring between 1 to 3 years of age and the hand 
use is sometimes preserved with minimal stereotypic hand movements (Weaving 
et al. 2004). The more severe forms include the “congenital variant” that lacks the 
early period of normal development, and the ‘‘early seizure variant’’ (ESV or 
“Hanefeld” variant), with onset of seizures before the age of 6 months (Hanefeld 
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1985). These variants present some symptoms of RTT, but show considerable 
variation in type and age of onset, severity of impairment, and clinical course.  
In 1999, Amir et colleagues discovered that mutations in the gene 
encoding methyl-CpG-binding protein 2 (MeCP2) [OMIM 300005] are associated 
with rare familial cases of RTT as well as more common sporadic occurrence of 
typical RTT (Amir et al. 1999). MeCP2 is a transcriptional repressor involved in 
chromatin remodeling and modulation of RNA splicing. Mutations in MECP2 are 
found in 95-97% of individuals with classic RTT (Neul et al. 2008), while only 
50-70% of patients with atypical variants of RTT have been diagnosed with 
mutations in MECP2, suggesting the existence of one or more RTT loci.  
Mutations in the CDKL5 gene [OMIM 300203] encoding for a serine-
threonine kinase (cyclin-dependent kinase like 5) have been identified in 
individuals who had been characterized as early-onset variant of RTT (ESV o 
“Hanefeld” variant), supporting the existence of genetic heterogeneity in RTT. 
However, the increasing identification of individuals with CDKL5 mutations has 
led to the observation that these individuals lack of some of the distinctive clinical 
features of classic RTT, such as the clear period of regression and the 
characteristic intense eye-gaze and very recently Fehr and colleagues proposed to 
consider the CDKL5 disorder as a distinctive disease (Fehr et al. 2013).  
Similarly, recent reports have identified mutations in a third gene involved 
in a variant of RTT. In 2008 Ariani and colleagues identified FOXG1-truncating 
mutations in two patients with congenital variant of RTT (Ariani et al. 2008). 
FOXG1 [OMIM 164874] encodes forkhead box protein G1, FoxG1 (formerly 
brain factor 1, BF-1), a brain-specific transcriptional repressor that is essential for 
early development of the telencephalon. Molecular analysis revealed that FoxG1 
might also share common molecular mechanisms with MeCP2 during neuronal 
development, exhibiting partially overlapping expression domain in postnatal 
cortex and neuronal subnuclear localization. 
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The incidence of the classic form of RTT is estimated at 1 out of 10,000 
females (Hagberg et al. 1983; Fehr et al. 2013). Current understanding of classical 
and variant forms suggests that the overall prevalence is probably higher. The 
annual death rate in classic RTT has been estimated about 1,2% in the UK (Kerr 
1992), and a little change in the survival has been found in the last 30 years 
(Freilinger et al. 2010). Most of death clustered between the ages of 15 and 20 
years with causes related to the disorder, such as wasted condition and poor health 
in general, pneuomonia and epilepsy. Poor autonomic control and autonomic 
manifestations are considered to play a significant role to (Julu et al. 2001).  
 
2.1.2. THE HISTORY OF RETT’S SYNDROME 
RTT was first described as a clinical entity by Andreas Rett, a pediatric 
neurologist in Vienna, in 1954. His publication in German medical literature in 
1966 (Rett 1966), however, remained largely unnoticed. In the large textbook 
series on neurology by Vincken and Bruyn, Andreas Rett wrote a chapter under 
the misleading heading of Cerebral Atrophy and Hyperammonaemia in a series of 
21 girls and women (Smeets et al. 2012). In the same time another child 
neurologist observed similar clinical features in Japanese girls (Smeets et al. 
2012), but only in 1983 Hagberg and colleagues increased awareness of the 
disorder in the English medical literature. They further described the condition in 
35 girls with strikingly similar clinical features of “progressive autism, loss of 
purposed hand movements, ataxia, and acquired microcephaly” (Hagberg et al. 
1983). This article was a breakthrough in communicating details of the disease to 
a wide audience and in 1986 Hagberg and Witt-Engerstroem developed the first 
classification of clinical staging of RTT, proposing four age-related stages, that 
was later revised in 2001 (Witt-Engerstrom and Hagberg 1990; Hagberg et al. 
2002). In addition to the worldwide recognition of RTT, the 1980s witnessed 
major strides in another field, namely DNA methylation. For the first time, a 
connection between DNA methylation and heritable changes in gene expression 
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was established. Scientists identified the CpG dinucleotide to be the side of almost 
all DNA methylation in mammalian genomes and began to define the effects of 
this modification on gene activity. In 1992, Dr. Adrian Bird and colleagues 
identified a novel mammalian protein that binds methylated CpGs, methyl-CpG 
binding protein 2 (MeCP2) (Lewis et al. 1992). The gene encoding MeCP2 was 
found to be localized to the X-chromosome (Quaderi et al. 1994) and the protein 
encoded was found to repress transcription in vivo (Nan et al. 1997). In the 
meantime, as the DNA methylation field was deciphering repression mechanisms 
mediated by methyl-CpG binding proteins, the RTT community tried to 
understand the pathophysiology of this puzzling condition. A major breakthrough 
in RTT research occurred in 1999, when researchers from Huda Zoghbi’s 
laboratory suggested the MECP2 gene as a candidate gene for RTT (Amir et al. 
1999). The identification of mutations in MECP2 as being causal in RTT has led 
to rapid increase in understanding the disease and numerous research groups are 
still trying to clarify the mechanism/s underlying this complex disorder.  
In the last years a small proportion of clinically well-defined RTT patients 
(3-5%) have been found not to present mutations in the MECP2 gene, suggesting 
the existence of at least one other RTT locus. Recently mutations in the gene for 
cyclin-dependent kinase like 5 (CDKL5) were identified in patients who had been 
diagnosed with atypical RTT, supporting the existence of genetic heterogeneity in 
this disease. The kinase CDKL5 was initially identified through a positional 
cloning study aimed at isolating disease genes mapping on the X-chromosome. 
Sequence analysis revealed homologies to several serine-threonine kinase genes 
and identified one protein signature specific for this subgroup of kinases, 
therefore, leading the authors to name the gene STK9 (Serine Threonine Kinase 9) 
(Montini et al. 1998). The first described mutations in CDKL5 were balanced 
X/autosomal translocations in two unrelated girls who, in addition to seizures and 
mental retardation, presented hypsarrythmia and infantile spasms (Kalscheuer et 
al. 2003). Even though the first patients mutated in CDKL5 were these two girls 
affected by X-linked infantile spasms (ISSX), subsequent cases were reported in 
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female patients with a clinical phenotype mimicking RTT (Tao et al. 2004; 
Weaving et al. 2004). The first genetic screening for CDKL5 mutations occurred 
mainly in cohorts of patients with RTT, or variants of it, which had no mutations 
in the MECP2 gene. By comparing the clinical phenotypes of patients with 
CDKL5 mutations already described in literature, it became clear that almost all of 
them presented one common characteristic: early onset seizures, starting from 10 
days to 3 months after birth. Therefore in the last years the screening has been 
extended to cohorts of both genders affected by undefined epileptic 
encephalopathy, infantile spasms or West Syndrome. Consequently individuals 
with mutations in the CDKL5 gene have been variably classified as having early 
infantile epileptic encephalopathy, X-linked dominant infantile spasm Syndrome, 
early-onset variant of RTT or diagnosed with other epileptic disorders such as 
West Syndrome. Interestingly, Intusoma et colleagues (Intusoma et al. 2011) 
suggested in a recent paper that screening among patients having intractable 
seizures with an onset before 6 months of age gives a higher score than screening 
among MECP2-negative RTT patients; this score is even increased when RTT- 
like features are shown as well. Only in 2013 Fehr and colleagues, using a large 
international data collection to describe the clinical profile of the CDKL5 disorder 
and comparing it with classical RTT, proposed to consider the CDKL5 disorder as 
an independent entity (Fehr et al. 2013). Although mutations in the CDKL5 gene 
have been for a long time described in association with the early-onset variant 
(ESV or “Hanefeld” variant) of RTT, Fehr’s paper describes, that only <25% of 
the analyzed cases meet the clinical criteria for this variant. They suggest that 
researchers and clinicians should not only concentrate on RTT features when 
describing the clinical picture of females and males with CDKL5 mutations, but 
they should also put the focus on the characteristic features present in the CDKL5 
disorder.  
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2.1.3. CLINICAL OVERVIEW  
RTT is characterized by a specific developmental profile and the clinical 
diagnosis is based on a consistent constellation of clinical features and 
internationally accepted diagnostic criteria delineated in a staging system (Fig. 1) 
(Witt-Engerstrom and Hagberg 1990; Hagberg et al. 2002; Neul et al. 2010). The 
diagnostic criteria include a neonatal and perinatal period with normal 
developmental progress for the first 5-6 months of life. The birth head 
circumference is normal with subsequent deceleration of head growth, leading 
usually to microcephaly. Between 3 months and 3 years of life there is a 
regression and loss of acquired skills, such as purposeful hand movements, 
vocalization, and communication skills. The hallmark of RTT is the intense, 
sometimes continuous, stereotypic hand movements, which develop after the loss 
of purposeful hand movements. Other motor abnormalities including abnormal 
muscle tone and jerky truncal gait are other prominent features. Many girls with 
RTT have also autonomic perturbations, including hypoventilation or 
hyperventilation during wakefulness, breath-holding, aereophagia, forced 
expulsion of air and saliva, and apnea.  
 
 
Figure 1 Staging system for classical RTT. Derived from Hagberg and Witt-
Engerstroem (Image taken from (Weaving et al. 2005)). 
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Common features in classical Rett’s Syndrome 
Hand stereotypies  
The hallmark and important diagnostic criteria for RTT are the intense, 
sometimes continuous, stereotypic hand movements, which develop after the loss 
of purposeful hand movements. Stereotyped hand movements are typically of 
small magnitude, but they may be accompanied by more proximal movements, 
that may also involve the trunk. Patterns consist of unimanual or bimanual 
wringing, mouthing, rubbing, patting, squeezing and/or clapping, or other more 
bizarre hand automatisms during waking hours (Fig. 2). 
 
 
Figure 2 Stereotypic hand movements in a girl with RTT (Image taken from 
(Borg et al. 2005)). 
 
Communication 
All the patients with RTT develop intellectual disabilities and mental 
retardation to a variable extent. The absence of speech, the dyspraxia and the short 
attention span with lack of interest in play are characteristic and make the 
developmental testing a difficult task. Affected children show diminished interest 
in people and objects and their exploratory character is very poor. Their 
16 
 
communication is often limited to establishing visual contact by intense staring 
and particular care should be taken to preserve this visual sensory function. No 
specific ophthalmologic pathology occurs in this disorder, although strabismus 
and acquired cataracts after self-injurious tapping in association with behavioral 
agitation is very common. Some affected girls have preservation of speech and 
can use words and sentences in a meaningful way.  
 
Kyphoscoliosis and Food Deformities 
Mild trunk hypotonia and lack of mobility often lead to kyphoscoliosis, 
which develops in early school age with various degrees of severity. Progression 
of scoliosis is often very rapid, depending on asymmetry in muscle tone 
(dystonia) and degree of muscle wasting. Most commonly an S-shaped curve 
develops with a longer upper part (most frequently dextroconvex) and a shorter 
lower part (sinistroconvex) (Fig. 3). Most common food deformities in RTT are 
equinus and equinusvalgus/varus positions due to the reduced intersegmental 
mobility, related to stereotyped postures or to dystonia.  
 
 
Figure 3 Scoliosis in a RTT patient (A) and X-ray view (B) (Image taken 
from (http://syndromepictures.com/rett-syndrome-pictures/)). 
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Seizures 
Epilepsy is present in up to 80% of affected individuals at some times in 
their lives (Steffenburg et al. 2001). It usually starts after the age of 4 years and 
becomes less intense in adulthood. The most common types are partial complex, 
tonic-clonic, tonic, and myoclonic seizures and solely about 50% of seizure in 
classical RTT can be controlled by medication. The electroencephalogram is 
usually abnormal in RTT, but there is none clearly diagnostic pattern. Brain stem 
events, such as blinking of the eyes, facial twitching, vacant spells and 
hypocapneic attacks are often confused with seizures.  
 
Autonomic Manifestations and Sleep Abnormalities 
Many girls with RTT have autonomic perturbations, including irregular 
breathing in the waking state associated with non-epileptic vacant spells. This 
includes hypoventilation or hyperventilation during wakefulness, breath-holding, 
aereophagia, forced expulsion of air and saliva and apnea. It reflects immaturity of 
the brainstem and may contribute to sudden death. Sleep abnormalities are more 
or less a constant feature in RTT and include night laughter, prolonged 
wakefulness or early morning awakening. The mechanism behind this disruptive 
night awakening and daytime sleeping is not well-understood, but may be related 
to the autonomic dysfunction that has been attributed to midbrain and brainstem 
immaturity.  
 
Feeding and Physical Growth  
Girls with RTT love to eat and like to watch when meals are prepared and 
are very alert during feeding. Emergence and control of primary mouth functions 
such as chewing and swallowing are often delayed and can be problematic. There 
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is also a high incidence of gastro-esophageal reflux and decreased intestinal 
motility resulting in constipation. In spite of the physical growth there is a 
deceleration of linear growth during the first 2 years of life, while later height 
and/or weight for height become normal. The rate of hand and foot growth, 
particularly the latter, of girls with RTT is slower than that of normal children. 
The birth head circumference is normal with subsequent deceleration of head 
growth, leading usually to microcephaly. The decline in head growth may thus be 
very obvious in classical RTT, but it may not be present at all in atypical variants 
of RTT. Therefore, microcephaly is no longer an essential criterion for the 
diagnosis. 
 
2.1.4. CLINICAL OVERVIEW OF THE CDKL5 VARIANT OF 
RTT 
The clinical characteristics commonly associated with CDKL5 mutations 
include early-onset seizures, severe intellectual disability and gross motor 
impairment. The recently published Neul criteria (Neul et al. 2010) for atypical 
RTT include five specific items for differentiating the early-onset variant (ESV or 
“Hanefeld” variant) from the classic form and the other atypical forms: seizures 
onset before 5 months of age, infantile spasms, refractory myoclonic epilepsy, 
seizures onset before regression and decreased frequency of typical RTT features 
(Table 1). 
For several years the clinical understanding of CDKL5 disorder was 
limited, with most information derived from small patient groups seen at 
individual centers, the largest including 20 patients (Bahi-Buisson et al. 2008). 
Fehr et al. in 2013 used a large international data collection (InterRett database; 
86 individuals with CDKL5 mutations and 920 individuals with MECP2 
mutations) to compare the clinical profile of CDKL5 disorder with classic RTT, 
concluding that CDKL5 disorder should be considered as an independent clinical 
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entity and should not be considered part of the RTT spectrum, as < 25 % of cases 
didn’t meet the clinical criteria for the early-onset variant of RTT (Table 2) (Fehr 
et al. 2013).  
 
 
 
Table 1 RTT diagnostic criteria 2010. (Table taken from (Neul et al. 2010)). 
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Table 2 Clinical features suggesting a diagnosis of CDKL5 disorder. 
(Image taken from (Fehr et al. 2013)). 
 
Seizures and motor delay 
The early-onset epilepsy is one of the hallmark features of the CDKL5 
disorder and occurs in about 90% of patients by 3 months of age. In literature 
many seizure types and EEG changes have been described, including infantile 
spasms, multifocal and generalized seizures with myoclonic, tonic (tonic 
vibratory) and clonic features. The second key feature characteristic for the 
CDKL5 disorder is a severe developmental motor delay. Fehr’s paper report that 
early development is more severely impaired in patients affected by CDKL5 
mutations, with approximately half learning to sit and 10% to walk in comparison 
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with 80% learning to sit and just half learning to walk affected of classic RTT 
(Fehr et al. 2013). 
Hand function and speech  
Patients with CDKL5 mutations develop less frequently typical hand 
stereotypies, which are the most important diagnostic criteria of the classic variant 
of RTT. Fehr et al. show that functional hand use was acquired by just over the 
half of the cases analyzed. Patients with CDKL5 disorder were less likely to use 
words whereas use of some words was acquired by nearly 90% of females with 
classic RTT before regression (Fehr et al. 2013). 
Dysmorphism  
Various dysmorphic facial features have been described in individuals 
with CDKL5 mutations including a prominent and/ or broad forehead, high 
hairline, relative mid-face hypoplasia, deep-set but “large” appearing eyes, 
infraorbital shadowing and strabismus. The lips appear full with often reversion of 
the lower lip. They also present often a wide mouth and widely spaced teeth. The 
fingers in young children are often tapered, some with puffy proximal and 
narrowed distal phalanges and some have a puffy dorsum of the hands and/ or 
feet. In older individuals, the fingers tend to be slender, with prominent proximal 
interphalangeal joints and narrow distal interphalangeal joints (Fig. 4).  
Dysmorphic features have also been described in other conditions of early-
onset encephalopathy, such as cases with FOXG1 mutations and in Pitt-Hopkins 
Syndrome, while in classical RTT no typical facial gestalt has been described, 
although some clinicians have suggested a facial similarity to Angelman 
Syndrome. The presence of these characteristic typical facial features could 
provide additional assistance in the clinical identification of individuals with a 
CDKL5 mutation.  
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Figure 4 Characteristic facial, hand and feet features in males and females 
with CDKL5 disorder. (Image taken from (Fehr et al. 2013)). 
 
 
In the last few years individuals with mutations in the CDKL5 gene have 
been variably classified and in most cases their symptoms have been attributed to 
the early-onset seizures variant of RTT (ESV or “Hanefed” variant), as they show 
some clinical overlapping phenotypes with the classic RTT. In literature CDKL5 
was considered part of the RTT spectrum and only in 2013 Fehr et colleagues 
suggested to consider the CDKL5 disorder as an independent clinical entity, 
basing on the observation that the majority of patients with CDKL5 mutations did 
not meet the diagnostic criteria proposed in 2010 by Neul et al. (Neul et al. 2010; 
Fehr et al. 2013). 
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2.1.5. CLINICAL MANAGEMENT AND THERAPEUTIC 
STRATEGIES 
Early clinical intervention and comprehensive life-long management of 
RTT are essential and can significantly improve health and longevity of affected 
individuals. Medical management is essentially symptomatic and supportive and 
may be optimized by involvement of a multidisciplinary team consisting of many 
different medical and paramedical specialists and by an individualized approach. 
Management should also include psychosocial support for the families, 
development of an appropriate education plan and assessment of available 
community resources. Parent support groups are crucial in providing support for 
families. Pharmacologic strategies targeting specific symptoms include anti-
epileptic treatments, treatment with L-carnitine, to improve patients’ wellbeing 
and health, magnesium to reduce the episodes of hyperventilation and melatonin 
to improve sleep dysfunctions. Clinical management should also include 
rehabilitation programs adapted to the patients’ individual needs, in order to 
improve posture and motility. Decreasing repetitive purposeless hand movements 
can for example be achieved by the use of various arm restraints, such as soft 
elbow splints, helping also in training specific hand skills such as self-feeding. 
Actually habilitation programs will likely remain the cornerstone of management 
of individuals with RTT, although a better understanding of the molecular 
pathophysiology of this condition is expected to lead to promising therapeutic 
approaches. 
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2.2. MeCP2 
 
2.2.1. THE MECP2 GENE AND ITS PRODUCTS 
The MECP2 gene is located at q28 on the human X chromosome and has 
been demonstrated to undergo X inactivation in human and mice (Adler et al. 
1995; D'Esposito et al. 1996). It encodes the methyl-CpG-binding protein MeCP2, 
which belongs to a large family of DNA-binding proteins that selectively bind 5-
methylcytosine residue in symmetrically positioned CpG dinucleotides. These 
nucleotides occur random throughout the genome; however, a recent study has 
shown that enrichment for A and T bases adjacent to methyl-CpG nucleotides is 
essential for high-affinity binding between MeCP2 and its target sites , indicating 
a basis for specificity (Klose et al. 2005). All proteins of this family contain a 
highly conserved MBD domain (methyl-CpG binding domain), which in MeCP2 
extends from position 1 to 174 and it is necessary and sufficient to bind DNA. 
MeCP2 contains a central transcriptional repressor domain (TBD), at position 
219-322, which is able to recruit co-repressor complexes that mediates repression 
through deacetylation of core histones, with consequent compaction of DNA into 
heterochromatin (Jones et al. 1998; Nan et al. 1998) and nuclear localization 
signal. The C-terminal domain facilitates the binding of MeCP2 to DNA(Chandler 
et al. 1999) and contains a WW domain that is predicted to be involved in protein-
protein interactions (Fig. 5) (Buschdorf and Stratling 2004).  
Two alternative spliced MECP2 transcripts has been identified: MECP2A 
(also known as MECP2_E2 or MECP2β, 498 amino acids) and MECP2B 
(MECP2_E1 or MECP2α, 486 amino acids) (Kriaucionis and Bird 2004; 
Mnatzakanian et al. 2004). The two splicing variants differ only in their most 5’ 
regions (Fig. 5). Although both of them are highly expressed in the brain, they 
differ in translation efficiency and are expressed at different relative amounts in 
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various tissues, with MECP2B being more prevalent and abundant in brain, 
thymus and lungs (Kriaucionis and Bird 2004), while MECP2A is highly 
expressed in other tissues, such as fibroblasts and lymphoblast cells 
(Mnatzakanian et al. 2004). Additional MECP2 transcripts with 3’UTRs of 
different lengths are also produced by the use of alternative polyadenilation sites. 
Their expression levels vary between tissues and developmental stages, but the 
functional significance of this is unknown.  
 
 
Figure 5 MECP2 gene and protein isoforms.  
Schematic illustration of the gene structure of MECP2 and the different 
domains of the two protein isoforms, MeCP2E1 and MeCP2E2. The primary 
amino acid composition of the N-terminus of MeCP2E1 and MeCP2E2 is 
depicted. 
(Image taken from (http://www.hindawi.com/journals/np/2012/415825/fig2)) 
 
The MeCP2 protein is present in all vertebrates, including the sea lamprey, 
a primitive jawless vertebrate, but no MeCP2 orthologous has been detected in 
invertebrate animals or plants. There are known MeCP2 orthologous in rat, 
mouse, monkey, Xenopus, and zebra fish, suggesting that MeCP2 has served 
important functions throughout vertebrate evolution, although these may be 
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different between widely divergent species. Sequences from human and mouse, 
for example, which diverged from a common ancestor, are 95% identical at the 
amino acid level. Divergences between mammalian MeCP2 and amphibian or fish 
MeCP2 is more extensive (33% amino acid identity between human and zebra 
fish), but conserved sequences as the MBD domain are present.  
 
2.3.2. MECP2 MUTATIONS AND THEIR INFLUENCE ON 
THE PHENOTYPIC OUTCOME 
 
Over the past few years, more than 2000 pathogenic mutations have been 
reported in females with RTT (Amir et al. 1999; Weaving et al. 2005). This 
includes missense mutations, nonsense mutations, frameshift mutations, large 
deletions and/or duplications. 70% of the reported alteration are due to C>T 
substitution in CpG hotspots in MECP2 and results in loss of function due to 
truncated, unstable or abnormally folded proteins. More recently, large 
rearrangements that involve MECP2, including deletions, were reported.  
 
Attempts to establish genotype-phenotype correlations in females with 
RTT give conflicting results, due to the phenotypic variability consequence of 
different pattern of X-chromosome inactivation. However some patterns have 
recently begun to emerge. Female patients with mutations in MECP2 that truncate 
the protein towards its C-terminal end (late-truncating mutations) have a 
phenotype that is less severe, and less typical of classic RTT, than patients who 
have missense or N-terminal (early truncating) mutations (Charman et al. 2005). 
In addition, the Arg270X mutation, which results in a truncated protein, is 
associated with increased mortality. This is consistent with greater clinical 
severity in cases with mutations upstream of or within the TRD domain. However, 
as missense and late-truncating mutations can lead to either classic or atypical 
RTT, it has been suggested that genetic background and/or non-random X-
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chromosome inactivation in the brain influence the biological consequences of 
mutations in MECP2. 
 
Mutations in MECP2 in males were initially thought to be prenatally 
lethal; however, it has been shown that these mutations cause a variable 
phenotype in males, ranging from mental retardation to severe encephalopathy. 
MECP2 mutations that cause classic RTT in females typically lead to neonatal 
encephalopathy and death in the first year of live in males with normal karyotype, 
while some mutations that do not cause RTT in females can cause moderate, 
nonspecific to profound mental retardation or psychiatric disorders in males.   
 
2.2.3. CURRENT PERSPECTIVES ON MeCP2 FUNCTIONS 
MeCP2 as a transcriptional regulator 
The prevailing view of MeCP2 function at the transcriptional level is 
largely based on a model of methylation-dependent binding and subsequent 
induction of transcriptional repression. MeCP2 binds to promoter regions 
containing methylated CpGs upstream of the transcription start site of target 
genes. This binding recruits co-repressor complexes through the interaction with 
the TBD domain (transcriptional repressor domain) and cause local chromatin 
compaction and consequent transcriptional down-regulation (Fig. 6A). 
MeCP2 binds to the methylated promoter of target genes and recruits 
chromatin-remodeling complexes that contain SIN3A (a transcriptional co-
repressor), BRM (a SWI/SNF-related chromatin remodeling protein) and histone 
deacetylases (HDACs). This leads to chromatin condensation owing to histone 
deacetylation, which results in a limited accessibility of the transcriptional 
machinery to the promoter of the target gene (Jones et al. 1998; Nan et al. 1998). 
MeCP2 also interacts with other co-repressors, such as SK1 viral proto-
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oncoprotein and the nuclear co-repressor NCOR, both of which are components of 
the HDAC complexes (Kokura et al. 2001). 
In regards to MeCP2 target genes, the initial attempts to identify such 
targets were heavily influenced by the model that MeCP2 acts solely as 
transcription repressor. In order to identify putative target genes in a high-
throughput, genome-wide manner, transcriptional profiling studies were 
performed. These early gene expression studies using either human post-mortem 
tissues or whole brain tissues from Mecp2-deficient animals, identified only a 
modest number of target genes and failed to support the role of MeCP2 only as 
transcriptional repressor (Colantuoni et al. 2001; Traynor et al. 2002; Tudor et al. 
2002; Nuber et al. 2005; Jordan et al. 2007). The identification of both up- and 
down-regulated genes argues against a single role of MeCP2 in transcriptional 
regulation and elucidates a limited or direct role of MeCP2 also in transcriptional 
activation (Fig. 6B). 
  
 
 
Figure 6 MeCP2 as a transcriptional regulator. 
(A) MeCP2 as a transcriptional repressor. MeCP2 binds to methylated CpG 
upstream of the transcriptional start site of MeCP2 target genes. This 
recruits repressive co-factors to presumably cause local chromatin 
compaction and transcriptional down-regulation.  
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(B) MeCP2 as a transcriptional activator. In this case, MeCP2 recruits a 
transcriptional co-activator to cause the transcriptional up-regulation of a 
target gene.  
(Image taken from (Samaco and Neul 2011)). 
 
MeCP2 as a histone-like protein 
Elucidating the transcriptional function of MeCP2 is further complicated 
by the recent evidence that MeCP2 is also a potent chromatin-condensing protein, 
which mediates the assembly of novel chromatin secondary structures 
independently of its binding to methylated DNA (Georgel 2007). This role of 
MeCP2 as histone-like protein was further confirmed by Skene et al. (Skene et al. 
2010). An important observation of this study is that neurons only have half the 
amount of histone H1 compared with non-neurons; in the absence of MeCP2, 
histone H1 increases in neurons up to the level of non-neuronal cells. This is 
accompanied by a global increase in acetylation state. These findings indicate a 
complex interplay between gene expression regulation in neurons that may 
involve compensatory mechanisms between MeCP2 and histone H1. Nevertheless 
more work is needed to determine the relationship between gene expression 
changes and MeCP2’s role as histone-like protein.  
 
MeCP2 regulation of imprinted genes 
An involvement of MeCP2 in the regulation of imprinted genes was first 
indicated by studies that showed subtly altered expression of UBE3A (ubiquitin 
protein ligase E3A), GABRB3 (γ-aminobutyric-acid receptor β3) and Dlx5 (distal-
less homebox 5) in patients with RTT and in Mecp2-deficient mice (Horike et al. 
2005; Makedonski et al. 2005; Samaco et al. 2005).  
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UBE3A, which encodes the ubiquitin ligase E3A, is located in an 
imprinted region, that has a causal role in Prader-Willi Syndrome (PWS) and 
Angelman Syndrome (AS). The imprinted expression of genes in this region 
involves a complex regulation that requires cis-acting elements, known as 
imprinting control regions (ICRs). The ICRs coordinate the expression of several 
neighboring genes and direct expression of genes within this region from the 
allele that is derived from one parent only, based on allele-specific epigenetic 
modifications of chromatin. The imprinting control region for the PWS-AS locus 
consists of two parts, with the AS ICR located more centromeric. Regulation of 
UBE3A expression also involves both a region that is located upstream of the 
nearby small nuclear ribonucleoprotein polypeptide N (SNRPN)-SNRPN upstream 
reading frame (SNURF) locus, known as the PWS-AS imprinting center, and the 
recently identified small nucleolar RNAs that overlap with UBE3A and are 
transcribed in the opposite direction. This transcript is also thought to inhibit the 
expression of UBE3A from the paternal allele through an antisense mechanism. 
UBE3A mRNA and protein levels are slightly reduced in MeCP2-deficient human 
and mice brains and UBE3A expression has been shown to be regulated by 
MeCP2. This downregulation of expression correlates with a biallelic production 
of UBE3A antisense RNA and changes in the chromatin structure, with increased 
acetylation and methylation of H3K4 (histone 3 lysine 4), and reduced 
methylation of H2K9 at the PWS-AS imprinting center. This indicate that MeCP2 
might regulate the interpretation of imprinted DNA-methylation marks in this 
region, in combination with other chromatin-binding proteins.  
MeCP2 can also regulate gene expression and maternal imprinting through 
the formation of a silent chromatin-loop. Horike et al. used chromatin 
immunoprecipitation to identify Mecp2-binding sites in mouse brains and 
revealed several sequences located within an imprinted gene cluster on 
chromosome 6, including Dlx5 and Dlx6 (Horike et al. 2005). The expression of 
these two genes is two times higher in the brains of Mecp2-null mice and 
interestingly the Dlx5-imprinted pattern is disrupted in these brains. Mecp2 has 
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shown to interact with sequences near the imprinted Dlx5 and Dlx6 genes, 
mediating the formation of a 11-kb chromatin loop at the Dlx5-Dlx6 locus that is 
enriched in methylated H39K. This leads to an integration of Dlx5 and Dlx6 into a 
loop of silent, methylated chromatin, and represses their expression. In Mecp2-
deficient brains this loop is absent and the expression of Dlx5 and Dlx6 is no 
longer repressed, which results in the over-expression of these two genes.  
 
MeCP2 as splicing regulator 
Another mechanism by which alterations in MeCP2 function might 
contribute to the characteristic features of RTT is through disruption of alternative 
splicing in the brain (Young et al. 2005). MeCP2 has been shown to interact with 
the YB1 protein (Y-box-binding protein 1, also known as p50 and EF1A), a 
principal component of messenger ribonucleoprotein particles that controls 
multiple steps of mRNA processing, including the selection of alternative splicing 
sites. The role of the MeCP2-YB1 complex was investigated by examining its 
function in the regulation of alternative splicing of candidate genes, such as 
NMDA receptor unit 1 (NR1) in vivo. The expression of NR1 is regulated by an 
alternative splicing event that is independent on neuronal activity and generates 
two functional variants. The comparison of wild-type and Mecp2-null mice 
showed significant differences in the amount of the two variants of NR1.  
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2.2.4. MECP2 TARGETS 
 
Brain-derived neurotrophic factor (BDNF)  
Two research groups (Chen et al. 2003; Martinowich et al. 2003) found 
that MeCP2 specifically binds to methylated CpG sites near the promoter III 
region of BDNF in rats and promoter IV region of BDNF in mice, respectively, 
thereby repressing BDNF transcription in resting neuronal cells. When the 
neurons where exposed to potassium chloride, which induce membrane 
depolarization, calcium influx and BDNF release, MeCP2 dissociated from the 
BDNF promoter. This displacement has been suggested to result from reduced 
CpG methylation in the relevant region of the activated promoter (Martinowich et 
al. 2003). An alternative mechanism has been proposed by Chen and his group, 
which showed a time-dependent increase in MeCP2 phosphorylation when 
neurons where stimulated with potassium chloride, which might influence the 
affinity of MeCP2 for the methylated promoter site (Chen et al. 2003). SIN3A, a 
MeCP2 co-repressor, is also displaced from the repressor complex after 
membrane depolarization induced by potassium chloride, and loss of MeCP2 is 
accompanied by changes in histone modification, which results in a 
transcriptionally permissive chromatin state.  
Although the specific functions of BDNF have not been completely 
elucidated, its important role in regulating synaptic plasticity and its effects as 
neurotrophic factor are well defined. A deficit in MeCP2 function and its 
downstream effects on BDNF expression might therefore account for the 
neurobiological and cellular defects observed in RTT. In support of this, 
transgenic mice that overexpress BDNF develop symptoms that are similar to 
those in Mecp2-deficient mice (Croll et al. 1999).  
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Hairy 2  
A recent study has identified another gene involved in neuronal 
differentiation as a target of MeCP2. In Xenopus, MeCP2 inhibits the expression 
of xHairy2a, which itself is a target of the Notch/Delta signaling pathway. With 
reduction of MeCP2 activity, xHairy2 expression is increased, and this leads to 
inhibition of primary neurogenesis (Stancheva et al. 2003). It will be interesting to 
study whether MeCP2 plays a role in other Notch regulated aspects of neuronal 
maturation.  
 
UBE3A (ubiquitin protein ligase E3A) 
UBE3A encodes for an ubiquitin ligase, an enzyme that is involved in the 
polyubiquitylation of target proteins in order to mark them for degradation. 
Mutations in the maternal allele of this gene (the paternal allele is normally 
inactivated in the brain due to paternal imprinting) are responsible for some cases 
of Angelman Syndrome, a genetic disorder characterized by hyperactivity, ataxia, 
problems with speech and language. If the paternally material from the same 
region is mutated instead, the brother syndrome, the Prader-Willi Syndrome, 
characterized by similar features such as mental retardation, learning disabilities 
and behavioral problems, is the result. MeCP2 regulates the imprinted gene 
UBE3A in a temporally and spatially defined manner and the deregulation of 
UBE3A expression that results from MeCP2 loss of function might contribute to 
the clinical manifestations of RTT, such as mental retardation, seizures, muscular 
hypotonia and acquired microcephaly, that overlap also with the other two 
disorders.  
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DLX5 (distal-less homebox 5) 
DLX5 regulates the production of enzymes that synthetize γ-amino butyric 
acid (GABA) and is overexpressed in Mecp2-deficient brains as a consequence of 
loss of imprinting. This might alter GABA-dependent neuron activity and 
contribute to the clinical manifestations of RTT.  
 
Glucocorticoid-regulated genes (Fkpb5 and Sgk1) 
Nuber et al. found that Mecp2-null mice differentially express several 
genes that are induced during the stress response by glucocorticoids. Increased 
levels of mRNAs for serum glucocorticoid-inducible kinase 1 (Sgk 1) and FK506-
binding protein 51 (Fkbp5) were observed before and after onset of neurological 
symptoms, but plasma glucocorticoid was not significantly elevated in Mecp2-
null mice. Mecp2 is bound to the Fkbp5 and Sgk genes in brain and may function 
as a modulator of glucocorticoid-inducible gene expression. Given the known 
deleterious effect of glucocorticoid exposure on brain development, this data 
raises the possibility that disruption of MeCP2-dependent regulation of stress-
responsive genes contributes to the symptoms of RTT (Nuber et al. 2005). 
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2.2.5. Mecp2 MOUSE MODELS 
To uncover the molecular mechanisms underlying MeCP2 dysfunction in 
the past few years several mouse models were generated.  
Mecp2 conditional male knockout mice (Mecp2-/Y), lacking either exon 3 
or both exon 3 and 4 (Chen et al. 2001; Guy et al. 2001), display severe 
neurological symptoms, including uncoordinated gate, hypoactivity, tremor, hind 
limb clasping and irregular breathing. Similarly to RTT patients they undergo a 
period of normal development, followed by severe neurological dysfunction, 
leading to death at 8-10 weeks of age. Behavioral testing of these conditional 
Mecp2 knockout models revealed phenotypes similar to RTT patients, including 
deficits in motor learning, increase in anxiety-like behavior, impairments in social 
interaction and altered learning and memory-related behaviors. Female Mecp2+/- 
mice show similar behavioral abnormalities, but with a later stage of onset. The 
brains of Mecp2-null mice are smaller in weight and size than brains of wild type 
littermates, but have no detectable structural abnormalities, except smaller, more 
densely packed neurons were found in hippocampus, cortex and cerebellum (Chen 
et al. 2001). In addition, the olfactory neurons of Mecp2-null mice demonstrate 
abnormalities of axonal targeting in the olfactory bulb, suggesting a function for 
MeCP2 in terminal neuronal differentiation (Matarazzo and Ronnett 2004). To 
elucidate the role of Mecp2-loss in the brain, a conditional KO approach, using a 
nestrin-Cre transgene, was used to specifically delete Mecp2 expression in the 
brain during early embryonic development. These mice show phenotypes similar 
to those observed in Mecp2-null mice, demonstrating that MeCP2 dysfunction in 
the brain is sufficient to cause the disease (Guy et al. 2001). Similar but less 
severe neurological phenotypes are observed when Mecp2 is only deleted in 
postmitotic neurons of broad forebrain regions using a calcium-calmodulin-
dependent kinase II (CaMKII)-Cre transgene, confirming an important role of 
MeCP2 in mature neurons (Chen et al. 2001; Gemelli et al. 2006). To further 
confirm the idea that MeCP2 is not essential for early brain development but has a 
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crucial role in mature neurons, Mecp2 was expressed under the control of the 
endogenous tau promoter in Mecp2-null mice and a total recovery of the 
neurological symptoms were observed (Luikenhuis et al. 2004). 
Shahbazian et al. created another mouse model, introducing a truncating 
disease-causing mutation in the murine Mecp2 gene (at amino acid 308) 
effectively deleting only the C-terminus end of Mecp2’s coding sequence 
(Shahbazian et al. 2002a). The Mecp2308/Y mice appear normal until 6 weeks of 
age, when they start to display impairments in motor learning, forepaw 
stereotypes, hypoactivity, tremor, seizures anxiety-related behaviors and deficits 
in social interactions. This model as well as female heterozygous mice for the 
truncation display milder and more variable traits.  
Transgenic mouse models with two-fold overexpression of human MeCP2 
under the control of its endogenous promoter (MECP2Tg) recapitulate many of the 
same behavioral phenotypes seen in Mecp2 KO mice, with the onset around 10 
weeks of age. Initially these mice display increased synaptic plasticity, with 
consequent enhancement in motor and contextual learning abilities, followed by 
social impairment, hypoactivity and motor deficits around 20 weeks of age. 
Mouse lines that overexpress MeCP2 have also been created by using a large 
insert genomic clone from a P1-derived artificial chromosome contacting MeCP2 
locus (Collins et al. 2004), demonstrating that higher levels of MeCP2 expression 
are associated with more severe phenotypes. Overexpression of MECP2 in adult 
neurons under control of the tau promoter also results in a progressive 
neurological symptomatology (Luikenhuis et al. 2004). These studies suggest that 
MeCP2 levels must be tightly regulated even postnatally and that the slightest 
perturbation results in deleterious neurological consequences.  
The characterization of these different mouse models clearly indicate that 
homeostatic regulation of MeCP2 is necessary for normal CNS functioning. Both 
the loss and the overexpression of MeCP2 result in neurological phenotypes 
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similar to those seen in patients with RTT, revealing a need for precise control 
over the amount of MeCP2 expression. 
 
2.2.6. THE ROLE OF MeCP2 IN THE BRAIN 
MeCP2 is an essential epigenetic regulator in human brain development. 
MECP2 mutations and dysfunctions, responsible for the classic form of RTT, 
have also been associated with a broad array of other neurodevelopmental 
disorders in males and females, including X-linked mental retardation (XLMR), 
severe neonatal encephalopathy, Angelman Syndrome (AS), and autism, 
demonstrating that disruption of MeCP2 can have wide-ranging effects on 
neurodevelopment and plays an important role during correct brain development 
(Hammer et al. 2002). 
 
MeCP2’s role in CNS development and neuronal maturation 
Patients with RTT display a normal period of development prior to 
symptom onset and then undergo a period of regression, suggesting that MeCP2 
may play a more functional role in early postnatal development rather than during 
embryonic periods. Additional confirmation has come from studying the timing of 
MeCP2 expression in both human and rodents. In the rodent CNS, MeCP2 
expression is first detected in the brainstem and spinal cord around day E12, while 
MECP2 mRNA is detected in subcortical regions at the beginning stages of 
embryonic neurogenesis (Shahbazian et al. 2002b; Jung et al. 2003). In thalamus, 
caudate putamen, cerebellum, hypothalamus and hippocampus MeCP2 expression 
starts at days E14-16, similarly to the cerebral cortex, where expression is first 
limited to the deeper cortical layers before spreading out to more superficial layers 
around day E18. Over the course of cellular differentiation, amounts of MeCP2 
38 
 
protein increase from early postnatal development into highly adulthood, in 
accordance with high MeCP2 expression in the mature brain (Shahbazian et al. 
2002b). In olfactory neurons, MeCP2 expression is also correlated with neuronal 
maturation (Cohen et al. 2003), during a period between neurogenesis and 
synaptogenesis. In humans this period occurs in the early embryonic week 12-20, 
and the loss of MeCP2 in RTT patients within this time window may be 
responsible for the observed decrease in neuronal and overall brain size. Autopsy 
studies show a 12%-34% reduction in brain weight and volume in patients with 
classic RTT, the effect most pronounced in the prefrontal, posterior frontal, and 
anterior temporal regions (Armstrong 2005). There is a decrease in the size of 
cortical minicolumns (Casanova et al. 2003), which is in accordance with the 
observation that there is a reduced dendritic branching of layers III and V of 
pyramidal neurons in frontal, temporal and motor regions, and of layer II and IV 
of the subiculum (Armstrong et al. 1995). At the same time, neurons of 
hippocampal CA1 and occipital regions are relatively preserved and although 
neuronal size is reduced in the cortex, thalamus, basal ganglia, amygdala and 
hippocampus, there is an increase in neuronal cell packing in the hippocampus 
(Kaufmann and Moser 2000). The loss of MeCP2 expression within the critical 
period for neuronal maturation and synaptogenesis, cumulating in an abnormal 
development of the CNS, may be responsible for the characteristic neuronal RTT 
phenotype. 
 
MeCP2 regulates dendritic morphology  
The reduction in brain size and neuron size seen in Mecp2-null mice and 
RTT patients is accompanied by a reduction in axonal and dendritic processes and 
decreased levels of the dendritic cytoskeletal protein MAP2 (microtubule 
associated protein 2). In addition neurons in RTT patients show a decrease of 
dendritic spine density (Armstrong 2002; Chapleau et al. 2009). In female RTT 
patients, CA1 pyramidal neurons exhibit decreased spine density (Chapleau et al. 
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2009) and MeCP2- deficient neurons have fewer dendritic spines and reduced 
arborization in the hippocampus and in the olfactory system (Zhou et al. 2006; 
Smrt et al. 2007; Palmer et al. 2008). Similar abnormalities in dendritic spines 
have been seen in human subjects with mental retardation and in animal models of 
Down syndrome (Kurt et al. 2000; Belichenko et al. 2004; Belichenko et al. 2007) 
and these dendritic abnormalities may contribute to the cognitive impairment in 
RTT patients (Fig.7).  
 
 
 
Figure 7 Model of neuronal pathology in RTT based on dendritic 
development in prefrontal cortex. 
During normal development, onset of MeCP2 expression coincides with 
early neuronal differentiation. Direct targets of MeCP2, such as BDNF, in 
conjunction with other synaptic signals have a particularly strong effect on 
the process of dendritic pruning. Marked reduction in MeCP2 function and 
deficient afferent input, in neurons carrying a MeCP2 mutated allele, impair 
appropriate dendritic expansion. The abnormality extends and worsens 
during dendritic puring because of the abnormally high levels of MeCP2 
targets and additional neurotransmitter disturbance. The ultimate neuronal 
phenotype is characterized by a smaller cell with markedly decreased 
MeCP2 expression and dendritic arborization.  
(Image taken from (Kaufmann et al. 2005)). 
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MeCP2 and synaptic transmission 
Long-term synaptic plasticity is widely accepted as the cellular basis for 
learning and memory, which can be observed as long-term potentiation (LTP) or 
long-term depression (LTD) of synaptic responses. LTP has been shown to be 
adversely affected in cortical and hippocampal slides of Mecp2-nullmice (Asaka 
et al. 2006¸Moretti, 2006 #86). A number of studies also show that MeCP2 KO 
hippocampal and cortical cultures display a significant decrease in spontaneous 
excitatory synaptic transmission, while inhibitory activity is increased (Dani et al. 
2005; Nelson et al. 2006; Chao et al. 2007). These changes in neurotransmission 
suggest an overall shift in the ration of excitation and inhibition and indicate that 
MeCP2 is essential in modulating synaptic function and plasticity.  
 
41 
 
2.3. CDKL5 
 
2.3.1. THE CDKL5 GENE AND ITS PRODUCTS 
 
The kinase CDKL5 was initially identified through a positional cloning 
study aimed at isolating genes mapping to Xp22 (Montini et al. 1998). The 
eukaryotic protein kinases represent a large superfamily of homologous proteins, 
related by the presence of a highly conserved kinase domain of 250-300 amino 
acids. There are two many subdivisions within the superfamily of eukaryotic 
protein kinases: the serine-threonine protein kinases and the protein tyrosine 
kinases. Sequence analysis revealed homologies to several serine-threonine kinase 
genes, and further characterization of the predicted protein product identified two 
protein kinase signature, one of which is specific for serine-threonine kinases. 
Consequently Montini et colleagues first named the identified gene STK9 (Serine 
Threonine Kinase 9). Serine-threonine kinases very frequently have been involved 
in the pathogenesis of genetic disorders and a number of human genetic disorders 
have been mapped to the Xp22 region. Montini et al. suggest the Nance-Horan 
syndrome (NH), a X-linked recessive disorder characterized by cataract and dental 
anomalies, as a candidate disorder for STK9 mutations. In the next five years, 
mutations in this gene were found in epileptic patients and in 2003 Vera 
Kalscheuer suggested STK9 to be a chromosomal locus associated with X-linked 
infantile spasms (ISSX) (Kalscheuer et al. 2003). The X-linked infantile spasm is 
characterized by early-onset generalized seizures, hypsarrhytmia and mental 
retardation and majority of cases are due to mutations in the aristaless-related 
homebox gene (ARX), which maps to the Xp21.3-p22.1 interval. Kalscheuer and 
colleagues in this paper show the disruption of STK9 in two unrelated patients 
with identical phenotype and suggest that the lack of functional STK9 protein may 
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be the second cause of this X-linked disorder. Given the strong similarity to some 
cell division protein kinases, the STK9 gene subsequently got renamed CDKL5 
(cyclin-dependent kinase like 5).  
The human CDKL5 gene occupies approximately 240 kb of the Xp22 
region and is composed of 24 exons of which the first three exons (exon 1, 1a and 
1b) are untranslated, whereas the coding sequence are contained within the exons 
2-21 (Fig. 8A). Following the identification of the human CDKL5 gene in 1998 by 
Montini et al., a number of different isoforms and splicing variants have been 
identified. Two different splice variants with different 5’UTRs have been 
identified: isoform I, containing exon 1, is transcribed in a wide range of tissues, 
whereas isoform II, including exon 1a and 1b, is limited to testis and fetal brain 
(Kalscheuer et al. 2003; Williamson et al. 2011). Alternative splicing events lead 
to three distinct human protein isoforms (Fig. 8B, C). The original CDKL5 
transcript generates a protein of 1030 amino acids and 115 kDa of molecular 
weight (CDKL5115) and is mainly expressed in the testis. Two other more recently 
identified transcripts, characterized by an altered C-terminal region, are likely to 
be relevant for CDKL5 brain functions (Fichou et al. 2011; Williamson et al. 
2011). Firstly, an alternatively spliced isoform has been described in both human 
and mouse, which has an additional in-frame exon of 123 bp, exon 16b, between 
exons 16 and 17, producing a predicted protein of 120kDa in humans and a 110 
kDa protein in mice (Fichou et al. 2011; Rademacher et al. 2011). Interestingly 
this variant is highly conserved in species through evolution, suggesting a 
potential functional role, but does not display any homology with other referenced 
sequences. Fichou et al. also demonstrate that the amount of exon 16b-containing 
(CDKL5115+ex.16b) transcript varied depending on the brain region analyzed and 
that this transcript is brain specific. The second isoform identified also in 2011 by 
Williamson et al. is a 107 kb isoform with an alternative C-terminus that 
terminates in intron 18 (CDKL5107) and is the predominant isoform in human and 
mouse brains, suggesting that this isoform is likely to be of primary pathogenic 
importance in the CDKL5 disorder. Although this is the major CDKL5 splice 
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variant, there are species-specific CDKL5 splice variants. Very recently, another 
previously unidentified CDKL5 splice variant producing a protein product with a 
variant C-terminus has been described in rat neurons and glial cells (Chen et al. 
2010). These isoforms have specific tissue distributions and end in rat exon 19, 
which is unique to the rat genome.  
 
 
 
 
Figure 8 The genomic structure of CDKL5 and its splice variants. 
(A) The human CDKL5 gene with untranslated sequences in grey and exons 
encoding the catalytic domain in blue. Exons encoding the common C-
terminal region appear in white, whereas isoform-specific sequences are 
shown in red, green, and as hatched.  
(B) hCDKL5 protein isoforms differing in the C-terminal region. CDKL5115 
contains the primate specific exons 19-21. In CDKL5107, intron 18 is 
retained. The inclusion of exon 16b would generate CDKL5115+ex.16b and/or 
CDKL5107+ex.16b. hCDKL5-ex19 is a hypothetical splice variant in which exon 
19 is excluded generating alternative C-terminus (light blue). 
(C) The murine CDKL5 isoforms. mCDKL5105 harbors a distinct C-terminal 
region encoded by a mouse specific exon 19 (orange). As in humans, the 
retention of intron 18 generates the common CDKL5107 isoform. 
(Image taken from (Kilstrup-Nielsen et al. 2012)).  
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The CDKL5 protein belongs to the CMGC family of serine-threonine 
kinases, which include cyclin-dependent kinases (CDKs), mitogen-activated 
protein kinases (MAP kinases), glycogen synthase kinases (GSK), and CDK-like 
kinases, and is characterized by a N-terminal catalytic domain (amino acids 13-
297), homologous to that of other CDKL-family members, such as 
p56KKIAMRE (CDKL1), p42KKIALRE (CDKL2) and NKIAMRE (CDKL3). 
This N-terminal catalytic domain contains the ATP-binding region (amino acids 
13-43), the serine-threonine kinase active site (amino-acids 131-143) and a Thr-
Xaa-Tyr motif (TEY) at amino acids 169-171, whose dual phosphorylation is 
normally involved in activating kinases of the MAP kinase family. In analogy to 
all the other members of the family of serine-threonine kinases, 12 conserved 
subdomains can be identified in this 284-amino acid kinase domain (Fig. 9).  
 
Interestingly, most of the pathogenic missense mutations identified so 
far hit the catalytic domain, suggesting that the enzymatic activity of CDKL5 
is essential for normal neurodevelopment.  
 
 
 
 
Figure 9 Schematic representation of the CDKL5 protein. (Image taken 
from (Bienvenu and Chelly 2006)).  
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CDKL5 is unique in his family of kinases as it presents an unusual long C-
terminal tail of more than 600 amino acids, highly conserved between different 
CDKL5 orthologous. This region contains putative signals for nuclear import 
(NLS) and export (NES) and seems to be involved in the cellular localization of 
the protein (Rusconi et al. 2008) and either the catalytic activity (Bertani et al. 
2006).  
 
 
2.3.2. CDKL5 MUTATIONS AND THEIR INFLUENCE ON THE 
PHENOTYPIC OUTCOME 
Since 2003, when Kalscheuer et al. identified the first mutations in CDKL5 
in two unrelated girls who, in addition to seizures and mental retardation, had 
hypsarrythmia and infantile spasms (Kalscheuer et al. 2003), patients with 
different phenotypic outcome of the disorder, harboring a wide range of 
pathogenic mutations, have been described in literature. More than 80 different 
point sequence variations have been described so far, including missense and 
nonsense mutations, small and large deletions, frameshift and splicing mutations. 
Even considering the small number of patients described, some “hot-spots” and 
genotype-phenotype correlations can be proposed. 
It has been suggested that missense mutations are mainly localized in the 
N-terminal catalytic domain, underlining the important role of the CDKL5 kinase 
activity during brain function and/or development. These mutations are associated 
with a more severe phenotype, characterized by early onset of intractable infantile 
spasms followed by late onset multifocal myoclonic epilepsy, while patients with 
stop-codon mutations in the long C-terminus of CDKL5 present a milder 
phenotype (Bahi-Buisson et al. 2008).  
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As previously described CDKL5 contains an ATP-binding motif and a 
conserved kinase catalytic domain in its N-terminus. The missense mutation 
p.Ala40Val in the ATP-binding domain has been described in 5 independent 
patients with common prominent autistic features. Compared to girls with other 
CDKL5 mutations these patients had better hand use and tend to present a better 
ability to walk, suggesting that mutations in the ATP-binding domain may result 
in a less severe phenotype (Bahi-Buisson et al. 2012). Even though the less 
number of cases described, some hot spots, as the ARG178-codon, located in the 
kinase catalytic domain, have been identified. Different missense mutations 
(p.Arg178Pro, pArg178Trp, pArg178Gln) have been identified at this codon, and 
it seems that the exchange of a positively charged amino acid such as arginine for 
an uncharged one (Pro, Trp and Gln), would likely influence substrate-binding 
specificity (Bahi-Buisson et al. 2012). Missense mutations in this catalytic kinase 
domain can be considered as loss-of function mutations as they impair the kinase 
activity of CDKL5 and generally result in a more several phenotypic outcome of 
the disease. Truncating mutations can be found anywhere in the gene, leading to 
CDKL5 derivatives of various length. Several truncating mutations, including the 
mutations p.Arg59X and p.Arg134X and the splice mutation c145+2T>C have 
been identified in the catalytic kinase domain, while different pathogenic 
mutations have also been found in the rather uncharacterized C-terminus of 
CDKL5. Some reports suggest that mutations in the C-terminus originate a milder 
clinical picture than those caused by mutations in the catalytic domain. 
Interestingly, the c.23635_2636delCT mutation, which leads to a protein 
truncation in position 908, is associated with a more severe phenotype, without 
affecting the catalytic domain (Bahi-Buisson et al. 2012).  
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Figure 10 Pathogenic CDKL5 mutations.  
(A) Schematic representation of CDKL5115 with the functional domains and 
signatures indicated. NLS: nuclear localization signal; NES: nuclear export 
signal. 
(B) All mutations in CDKL5 reported to date are indicated corresponding to 
their location within the gene. Mutations shown above the CDKL5 gene are 
deletion and frame shift mutations as well as splice variants indicated with 
cDNA nomenclature. Missense and nonsense mutations (fuchsia and black, 
resp.) are represented with amino acid nomenclature below the CDKL5 
gene. 
(Image taken from (Kilstrup-Nielsen et al. 2012)). 
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2.3.3. CURRENT PERSPECTIVES ON CDKL5 FUNCTIONS 
 
CDKL5 might regulate the function of epigenetic factors and 
transcriptional regulators 
 
The first demonstrating the phosphorylation activity of CDKL5 were Mari 
et al. in 2005. Considering the similar phenotypes caused by mutations in MECP2 
and CDKL5, they investigated the expression patterns of both proteins in 
embryonic and postnatal mouse brains. MeCP2 and Cdkl5 show a spatial and 
temporal overlapping expression during neuronal maturation and synaptogenesis 
in the brain, in favor of a possible involvement of the two proteins in the same 
development pathway (Mari et al. 2005). They also investigate whether MeCP2 
and CDKL5 directly interact in vitro and in vivo. By classical pull-down assays 
Mari et colleagues demonstrated that MeCP2 and CDKL5 are directly interacting 
in vitro and that a portion on MeCP2, containing the last residues of the TRD and 
the C-terminal region, is responsible for this association. An analog interaction 
was demonstrated also in vivo by co-immunoprecipitation experiments. Given the 
direct interaction between MeCP2 and CDKL5 and the overlapped expression in 
different brain regions, they further investigated whether CDKL5, based on the 
sequence homologies with other kinases, is able to autophosphorylate and to 
phopsphorylate MeCP2. 
 
Their results demonstrate that CDKL5 is indeed a kinase, which is able to 
autophosphorylate itself and to mediate also MeCP2 phosphorylation, suggesting 
that these proteins belong to the same molecular pathway. There are some 
controversial results from another research group, which was able to demonstrate 
the autophosphorylate capacity of CDKL5 to, but not to confirm that CDKL5 is a 
direct target of  MeCP2, neither ARX, the gene responsible for the X-linked 
infantile spasms (Lin et al. 2005). 
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Furthermore, a recent report has suggested a new link between CDKL5 
and MeCP2. Both proteins have been shown, indeed, to bind to DNA 
Methyltransferase 1 (DNMT1), an enzyme that recognizes and methylates 
hemimethylated CpG dinucleotides after DNA replication to maintain a correct 
methylation pattern (Kameshita et al. 2008). More recently Carouge and 
colleagues addressed the question of the transcriptional control of Cdkl5 by 
Mecp2 as a potential link between the two genes, taking advantage of MeCP2 
induction by cocaine in rat brain structures (Carouge et al. 2010). Their data 
reveal that over-expression of Mecp2 in transfected cells results in the repression 
of Cdkl5 expression and that in vivo Mecp2 directly interacts with Cdkl5 gene in a 
methylation-dependent manner. Taken together these results are consistent with 
Cdkl5 being a Mecp2-repressed target gene and provide new insights into the 
mechanism by which mutations in the two genes result in overlapping 
neurological symptoms (Carouge et al. 2010). 
 
An interesting feature of CDKL5 that distinguishes it from MeCP2 is its 
subcellular localization. While MeCP2 is only a nuclear protein, CDKL5 seems to 
shuttle between the nucleus and the cytoplasm. The subcellular localization of 
CDKL5 within the cell seems to be important also for its function. In the nucleus 
CDKL5 co-localizes and is associated with a number of splicing factors that are 
stored in structures called nuclear speckles, in both cell lines and tissues. In these 
structures CDKL5 seems to manage the nuclear trafficking of splicing factors and 
thus indirectly of the splicing machinery (Ricciardi et al. 2009). It is already 
known that phosphorylation of the RS domain of Serine-rich (SR) splicing factors 
is necessary to release these factors from speckles and direct them to sites where 
pre-mRNA processing takes place. Considering that several protein kinases have 
been described to be able to phosphorylate the RS domain of SR proteins, 
Ricciardi and colleagues have hypothesized that also CDKL5 could have a role in 
nuclear speckles organization. Interestingly it has been demonstrated that CDKL5 
acts on nuclear speckle disassembly determining a redistribution of at least some 
speckle proteins (Ricciardi et al. 2009). These results suggest that CDKL5 may 
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play a role in controlling gene expression through phosphorylation of DNMT1 
and alteration of CpG methylation, which may affect the transcription of 
numerous genes. In addition, altering the distribution of the splicing factor 
machinery within the nucleus may result in alternative splicing of different RNA’s 
leading to a subset of proteins with subtly altered functions. Rosas Vargas et al. 
looked at the effect of two missense mutations (p.Ala40Val and p.Leu220Pro) 
causing severe infantile encephalopathy on cellular distribution. These mutations 
are both within the catalytic domain of CDKL5 and therefore likely to affect 
phosphorylation. In both cases the proteins were unable to cross into the nucleus 
suggesting that the phosphorylation state of CDKL5 may regulate its ability to 
enter the nucleus (Rosas-Vargas et al. 2008). 
 
 
Cdkl5 expression correlates with neuronal maturation 
 
Expression studies in human and mouse tissues have shown that 
CDKL5/Cdkl5 mRNA is present in a wide range of tissues, with highest levels of 
expression in the brain, underlining its importance for the nervous system 
functions. Comparing the expression levels of Mecp2 and Cdkl5 in mouse brains, 
Rusconi and colleagues demonstrated that Mecp2 expression is induced during 
embryogenesis and its levels remain rather constant during postnatal stage until 
adulthood, while Cdkl5 expression is very low during embryonic stages and is 
highly induced during the first two postnatal weeks, and after this period it 
declines (Fig. 11H) (Rusconi et al. 2008). Moreover Cdkl5 levels also vary in the 
different brain regions in adulthood, with highest levels in the cortex, 
hippocampus, and striatum. Interestingly very high expression levels are detected 
in the most superficial cortical layer, particularly involved in the connection of the 
two hemispheres through the corpus callosum, suggesting a possible role of 
CDKL5 in this brain region. In the hippocampus Cdkl5 mRNA is present at high 
levels in all the CA fields, while it presents lower expression in the dentate gyrus 
(DG), in accordance with the fact that DG neuronal maturation occurs mainly in 
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adulthood. Surprisingly compared to the other brain regions low levels of Cdkl5 
were found in the cerebellum (Fig. 11) (Rusconi et al. 2008).  
 
 
 
Figure 11 Cdkl5 expression is highly induced at early postnatal stages of 
brain development. 
(A-G) Immunohistochemistry experiments showing Cdkl5 expression in the 
cortex (A-D) and hippocampus (E-G) of mouse brains at different embryonic 
or postnatal stages. 
(H) Western blot showing Cdkl5 and Mecp2 levels in the total brain at 
different embryonic and postnatal stages.  
(I) Western blot showing Cdkl5 and Mecp2 levels in different brain area of 
adult mice (P120)  
(Image taken from (Rusconi et al. 2008)). 
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As mentioned, CDKL5 seems to shuttle between the nucleus and the 
cytoplasm. In the mouse brain, Cdkl5 is initially predominantly cytoplasmatic and 
progressively accumulates in the nucleus, starting from roughly P14 when 
approximately 40% of total Cdkl5 can be detected in this cellular compartment. 
However, Cdkl5 gets significantly translocated to the nucleus only in certain brain 
areas; in the cerebellum for example more than 80% of Cdkl5 remains 
cytoplasmatic, while in the cortex it is almost equally distributed between the two 
compartments (Rusconi et al. 2008). The nuclear fraction increases during early 
postnatal stages consistently with neuronal maturation and remains as such until 
adult stages, suggesting that CDKL5 functions might be modulated through 
mechanisms regulating its shuttling between nucleus and cytoplasm. In 
accordance with this, Rusconi et al. also demonstrated that the C-terminal region 
of CDKL5 is important for its subcellular dynamic localization (Rusconi et al. 
2008). 
 
At the cellular level, CDKL5 is easily detectable in virtually all NeuN-
positive neurons while it is expressed at very low levels in the glia (Rusconi et al. 
2008), in accordance with an important role of CDKL5 in neuronal maturation 
and function. In cultured non-neuronal cells exogenous CDKL5 shuttles 
constitutively between the nucleus and the cytoplasm through an active nuclear 
export-dependent mechanism, which involves the C-terminus of CDKL5 and the 
CMR1 nuclear export receptor. Interestingly Rusconi and colleagues observed 
that a similar mechanism is not present in rat hippocampal neurons and this result 
integrated with the knowledge that Cdkl5 is mainly cytoplasmic in young brains 
and moves into the nucleus upon neuronal maturation suggests that, in neurons, 
CDKL5 is not dynamically cycling between the nucleus and cytoplasm. Cdkl5 
intracelluar trafficking occurs in rat hippocampal neurons after specific 
stimulation with glutamate through an active nuclear export system. This 
phenomenon needs further investigation, but it might be hypothesized that 
CDKL5 plays different roles also depending on the specific neuronal 
subpopulation (Rusconi et al. 2011). In addition, it has been found that sustained 
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glutamate stimulation promoted CDKL5 proteasomal degradation and that 
degradation of CDKL5 itself seems to be involved in regulating its function. Both 
events are mediated by the specific activation of extrasynaptic pool of N-methyl-
D-aspartate receptors. Proteasomal degradation was also induced by withdrawal 
of neurotrophic factors and hydrogen peroxide treatment, two different paradigms 
of cell death. Altogether, these results by Rusconi et al. indicate that both 
subcellular localization and expression of CDKL5 are modulated by the activation 
of extrasynaptic N-methyl-D-aspartate receptors and suggest a regulation of 
CDKL5 by cell death pathways (Rusconi et al. 2011). Why neurons degrade 
CDKL5 upon cell death induction and how this degradation is regulated are still 
unanswered questions. 
 
 
CDKL5 affects neuronal morphogenesis and dendritic 
arborization 
 
As already mentioned, CDKL5 expression correlates both in vitro and in 
vivo with neuronal maturation, reaching the highest levels of expression when 
neurons acquire a mature phenotype and suggesting an involvement of the kinase 
in neuronal differentiation and arborization. Chen et al. recently demonstrated that 
Cdkl5 affects neuronal morphogenesis and dendritic arborization through a 
cytoplasmic mechanism. In cortical rat neurons down regulation of Cdkl5 by 
RNA interference inhibits neurite outgrowth and dendritic arborization, while 
overexpression had opposite effects (Chen et al. 2010). They also found out that 
in fibroblasts and neurons CDKL5 co-localizes with F-actin in the growth cone 
and forms a protein complex with Rac1, a critical regulator of actin remodeling 
and neuronal morphogenesis. Rac1 belong to the Rho GTPas family of proteins 
that promote the formation and/or maturation of spines by remodeling the actin 
cytoskeleton of neuronal spines (Chen et al. 2010). Functional experiments 
suggest that CDKL5 influences neuronal morphogenesis by acting upstream of 
Rac1. Chen et al. also demonstrated that brain-derived neurotrophic factor 
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(BDNF) transiently phosphorylates CDKL5 and CDKL5 is necessary for the 
capability of BDNF to activate Rac1 (Chen et al. 2010). These results confirm a 
critical role of CDKL5 in neuronal morphogenesis and suggest that deregulation 
of the BDNF-Rac1 signaling pathway may contribute to the neuronal phenotype 
of the CDKL5 disorder.  
 
 
Figure 12 A model depicting the different functions of CDKL5 in the 
cytoplasmic and nuclear compartments. 
(A) In the cytoplasm CDKL5 is involved in the regulation of actin 
cytoskeleton and dendritic arborization. This function is mediated by the 
interaction of CDKL5 with Rac1. Importantly, a link between BDNF and 
Rac1 activation has been suggested. (Chen et al.; 2011).  
(B) In the cytoplasmic compartment, the levels of CDKL5 are regulated by 
degradation. Furthermore several phosphorylation targets remain to be 
identified.  
(C) In the nucleus, CDKL5 has been proposed capable of interacting and 
phosphorylating MeCP2 and DNMT1, thereby influencing gene expression 
and DNA methylation. Furthermore, the protein has been shown to 
colocalize with RNA speckles involved in RNA splicing. Several targets have 
not been identified so far. 
(Image taken from (Kilstrup-Nielsen et al. 2012)). 
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CDKL5 contributes to correct dendritic spine structure and 
synapse activity 
 
The important role of CDKL5 in neuronal morphogenesis was further 
confirmed by Ricciardi and colleagues, which demonstrated that CDKL5 
contributes to correct spine structure and synapse activity. Ricciardi et al. 
demonstrated that CDKL5 localizes almost exclusively at the post synaptic 
density (PSD) of excitatory synapses both in vivo and in vitro. CDKL5 silencing 
in rat hippocampal neurons leads to severe deficits in spine density and 
morphology and similar alterations have been found in neurons established from 
patient fibroblast-derived pluripotent stem cells (iPSCs), indicating that CDKL5 is 
required for ensuring a correct number of well-shaped spines. In line with the 
compromised development of spines, CDKL5-downregulated neurons exhibit a 
significant decrease in spontaneous miniature excitatory postsynaptic currents 
(mEPSCs), while there was no significant effect on inhibitory synapse density or 
any significant changes in miniature inhibitory postsynaptic currents (Ricciardi et 
al. 2012). These data suggest that CDKL5 is a key-limiting factor in regulating 
glutamatergic synapse formation and that changes in excitatory synaptic strength 
might be responsible, at least in part, for the neurodevelopmental symptoms 
associated with this disorder.  
 
Ricciardi and colleagues also demonstrated that CDKL5 interacts and 
phosphorylates the netrin-G1 ligand (NGL-1, also known as LRRC4C), a synaptic 
cell adhesion molecule (CAMs) that plays a crucial role in synapse homeostasis. 
NGLs have a conserved C-terminal PDZ-binding domain, which specifically 
binds to PSD95, a protein that plays a significant role in learning and memory, 
and NGL-1 spine-inducing capability is promoted by targeting PSD95 to new 
forming dendritic protrusions. CDKL5 phosphorylates NGL-1 on a unique serine 
(Ser631), which is very close to the PZD-binding domain and this 
phosphorylation event ensures a stable association between NGL-1 and PSD95 
(Ricciardi et al. 2012). These data indicate that CDKL5 is critical for the 
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maintenance of synaptic contacts, mainly by regulating the NGL-1 
phosphorylated state and, thereby, its ability to bind PSD95 and stabilizes this 
association.  
 
More recently another research group confirmed the critical role of 
CDKL5 in regulating spine development and synapse activity, demonstrating that 
CDKL5 binds directly to PSD95 in a palmitoylation-dependent way (Zhu et al. 
2013). The multidomain protein postsynaptic density (PSD) 95 is a major scaffold 
in the postsynaptic density and has an essential role in synapse development and 
maturation. Its N-terminal domain is posttranslationally modified by 
palmitoylation, a reversible attachment of 16-carbon palmitate to a cysteine 
residue, and this palmitate cycling on PSD95 controls its polarized targeting to 
synapses, which is essential for its synaptic function. Zhu and colleagues 
demonstrated that CDKL5 binds to palmitolyated PSD95 and that this binding 
promotes the targeting of CDKL5 to excitatory synapses. They propose two 
possible ways by which palmitolyated PSD95 regulates synaptic targeting of 
CDKL5. First, CDKL5 may bind to palmitolyated PSD95 at the Golgi apparatus 
and the complex moves to the postsynaptic side. Second and more likely 
important in neurons, free CDKL5 is captured by newly palmitolyated PSD95 at 
the dendrites and then trafficked to synapses, and becomes enriching at the 
subsynaptic side. Taken tighter these results demonstrate a critical role of the 
palmitoylation-dependent CDKL5-PSD95 interaction in localizing CDKL5 to 
synapses for normal spine development.  
 
These data imply that two pathways are important in mediating the 
cytoplasmic function of CDKL5: first of all CDKL5 is required for BDNF-
induced activation of Rac1, which participates in stabilizing the actin 
cytoskeleton; on the other hand CDKL5, PSD95  and NGL-1, form a protein 
complex that functions coordinately to regulate synapse development. These data 
show that different CDKL5-signaling cascades are involved in synaptic plasticity 
and learning, acting on spines, dendritic branching and actin cytoskeleton and 
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elucidate, in part, how the lack of CDKL5 may contribute to the typical neuronal 
phenotype of the CDKL5 disorder, characterized by intellectual disability, early-
onset epilepsy and autistic features.  
 
Another recently identified cytoplasmatic target of CDKL5 is amphiphysin 
1 (AMPH1), a brain specific protein involved in neuronal transmission and 
synaptic vesicle recycling through clathrin-mediated endocytosis (Sekiguchi et al. 
2013). Sekiguchi and colleagues explored the endogenous substrates of Cdkl5 in 
mouse brains extracts using a newly developed method and found Amph1 as 
specific substrate of Cdkl5. They demonstrated that Cdkl5 phosphorylates Amph1 
exclusively at Ser 293 and that this phosphorylation is disrupted by Cdkl5 
catalytic domain mutations. Interestingly Cdk5 also phosphorylates Amph1 but at 
different positions (Ser-272, 276 and 285) to that of Cdkl5 (Sekiguchi et al. 2013). 
It still remains unclear what effect phosphorylation of AMPH1 by CDKL5 has on 
its function in neuronal development, but interestingly Amph1 deficient mouse 
shows major learning difficulties and irreversible seizures, suggesting that Amph1 
is a critical molecular component of the pathogenic pathway of the CDKL5 
disorder.  
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2.4. NEUROGENESIS IN THE POSTNATAL BRAIN 
 
CDKL5 expression correlates, both in vitro and in vivo, with neuronal 
maturation, reaching the highest levels of expression during postnatal 
development, when neurons acquire a mature phenotype, suggesting an 
involvement of this kinase in neuronal differentiation and arborization (Rusconi et 
al. 2008; Chen et al. 2010; Rusconi et al. 2011). Considering its temporal 
expression pattern, CDKL5 might have an important role also in postnatal and 
adult neurogenesis. Impairment of adult neurogenesis has been observed in a 
variety of models relevant to neuropsychiatric diseases, such as major depression, 
schizophrenia and Alzheimer’s disease, and neurodevelopmental disorders, 
including Fragile X and Down syndrome (DS).  
 
Noteworthy, neurogenesis persists in the postnatal and adult brain in two 
distinct brain regions, the subventricular zone (SVZ) and the hippocampal dentate 
gyrus (DG).  
 
 
2.4.1. POSTNATAL NEUROGENESIS IN THE SVZ 
 
In the central nervous system of mammals, most neurons are generated in 
two specific regions that form the germinal ventricular system: the ventricular 
zone (VZ) and the subventricular zone (SVZ). The cells from the VZ descend 
directly from the neural plate, and give rise to post-mitotic neuroblasts that 
migrate up in a radial direction to the surface of the pia mater. At E16 in the 
mouse brain, these cells leave the cell cycle (Haydar et al. 2000) and during early 
postnatal development the VZ disappears completely, while the number of cells in 
the SVZ reaches a peak in the first postnatal week in rodents (approximately the 
35th gestational weeks in humans). After this period there is a gradual decrease in 
size, but a region of small mitotically active SVZ persists also into adulthood.  
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During development the SVZ is divided into four regions: MGE (medial 
ganglionic eminence), LGE (lateral ganglionic eminence), CGE (caudal 
ganglionic eminence) and SVZn (foetal neocortical SVZ). Each region presents 
different progenitors, which generate neurons and glia that populate different 
areas of the developing brain. The VZ, SVZn, MGE, LGE and CGE give rise to 
neurons that populate the neocortex, striatum, thalamus, hippocampus and other 
subcortical structures. The MGE and LGE disappear in the postnatal period.  
 
In the perinatal period, the SVZ can be subdivided into two key anatomical 
regions: the anterior SVZ (SVZa) and the SVZ back side (SVZdl) regions. The 
first one is the main source of the cells of the RMS (rostral migratory stream), 
while the SVZdl gives rise to the neuroglia of the telencephalon. The migration of 
cells from the SVZa region through the RMS to the olfactory bulb occurs in forms 
of cell chains and, once reached the bulb, individual cells disperse radically 
(Alvarez-Buylla 1997). SVZdl cells migrate into the white matter and then rotate 
90 degrees to reach the neocortex. In mice at the second day after birth (P2) 80% 
of the progeny cells derived from SVZdl cells migrate into the neocortex, 10% in 
the white matter and the remaining percentage of marked cells colonize the 
surrounding regions (Brazel et al. 2003). The SVZdl region is the main source of 
macroglia. In the grey matter, the cells which leave the SVZ in the early perinatal 
period, differentiate in astrocytes, while in the white matter this differentiation is 
not allowed. SVZdl cells which migrate into a more advanced stage of 
development differentiate primarily in myelinated and non-myelinated 
oligodendrocytes,, and NG2+ cells. Oligodendrocytes have been observed in the 
neocortex (where the precursors are mitotically active), in the striatum and in the 
subcortical white matter. 
 
 
The ultrastructure and organization of the adult SVZ has been recently 
studied in detail and there have been identified four cell types (excluding resident 
microglia). These cells were classified as types A, B1, B2 and C. The cells of type 
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A are small, intensely marked and correspond to neuroblasts destined to the 
olfactory bulb, while the cell types B1 and B2 show the characteristics of 
astrocytes. B1 cells are immature astrocytes, whereas B2 cells are probably neural 
stem cells. C cells, the fourth cell type, appear larger and isolated in clusters. They 
are very mitotically active and are transient multipotent cells (Fig. 13). 
 
Electron microscopy combined with staining with 3H-thymidine have 
shown that the migrating cells in the RMS belong to type A. Immature progenitor 
cells in the SVZ in adulthood continue to migrate through the RMS in the 
olfactory bulb, where cells mature into post-mitotic neurons in the granular layer 
and around the glomeruli (Lois et al. 1996). It has been estimated that in the adult 
mouse brain there are approximately 1200 neural stem cells.  
 
 
 
 
Figure 13 Model of neurogenesis in the subventricular zone (SVZ) 
/olfactory bulb system.  
1. Proliferation and fate determination: Stem cells in the SVZ of the lateral 
ventricle (blue) give rise to transit amplifying cells (green) that differentiate 
into immature neurons (red). Adjacent ependymal cells (light brown) of the 
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lateral ventricle are essential for the neuronal fate determination by 
providing inhibitors of glial differentiation.  
2. Migration: Immature neurons (red) migrate along each other in chains 
through the rostral migratory pathway (RMP). The migrating neurons are 
ensheathed by astrocytes (blue).  
3. Integration: Immature neurons differentiate local interneurons (red) in 
the granule cell layer and the periglomerular layer. Olfactory sensory 
neurons (OSN); tufted neurons (T); mitral neurons (M); granule neurons 
(Gr); periglomerular neurons (PG).  
(Image taken from (Lie et al. 2004))  
 
 
Many studies show that the SVZ responds to damage in the adult brain by 
producing new progenitor cells that migrate to sites where there had been a 
neurodegeneration or a brain injury. In response to diseases such as epilepsy or 
Huntington's syndrome it is observed an increase of stem cells, cytokine levels 
and migration proteins in the SVZ (Curtis et al. 2007). 
 
 
2.4.2 POSTNATAL NEUROGENESIS IN THE DG 
 
The hippocampus is integral to learning and memory function and 
evidences suggest that adult hippocampal neurogenesis is involved in acquisition 
of declarative memory in the short and long term and other hippocampal functions 
(Zhao et al. 2008). If the hippocampus is damaged facts and events cannot be 
stored over a long-term memory. Given its fundamental importance in learning 
and memory, the hippocampus has always been the subject of intense anatomical 
psychological and psychophysical studies. The main structures of the 
hippocampal formation are the entorhinal cortex (EC), the dentate gyrus (DG), 
CA3 and CA1 regions and the subiculum. 
 
The hippocampal dentate gyrus (DG) is formed over a long time period 
that begins during gestation and continues in the postnatal period. It contains a 
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neurogenic niche, the subgranular zone (SGZ), which is inhabited by a 
heterogonous population of cells and cellular elements, which play an important 
role in neurogenesis. Type 1 neural stem cells (NSCs) are radial glia-like 
progenitors and express the markers nestin and Sox2/BLBp. It is hypothesized 
that these cells divide asymmetrically to self-renew and give rise to daughter cells, 
termed actively dividing progenitors (type 2, type 3 cells). Type 2 cells are 
differentiated into two different subtypes: type 2a or type 2b cells. Type 2a 
progenitor cells are nestin-positive, and their morphology suggest that they are 
capable of tangential migration (Kuhn et al. 1996). On the other hand type-2b 
cells are also considered actively dividing progenitor cells but, unlike type-2a 
cells, they have limited self-renewal capabilities and are lineage determined. In 
addition to nestin, type 2b cells also express doublecortin (DCX), similar to type 3 
cells which only express DCX. After progressing through these stages, precursors 
exit the cell cycle and enter a post-mitotic stage, where they are termed immature 
granule cells and actively establish network connections. The final stage of 
differentiation is the post-mitotic, mature granule cell (DGCs) that expresses the 
neuronal marker NeuN. These cells are considered to be terminally differentiated 
granule cells and project their axons (known as mossy fibers) to CA3 pyramidal 
cells and their dendrites to the molecular layer (Fig. 14). 
 
Adult-born neurons make up about 6% of the granule cell layer in adult 
rats (Cameron and McKay 2001) and newly generated granule cells are 
continuously integrated into the hippocampal circuit as bromodeoxyuridine 
(BrdU) labeling studies indicate (van Praag et al. 2002). 
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Figure 14 An overview of hippocampal neurogenesis. (Image 
taken from (Masiulis et al. 2011)). 
 
 
Increasing evidence supports a role for adult-born neurons in learning and 
memory. Stimulation of adult hippocampal neurogenesis with behavioral 
interventions such as exercise or environmental enrichment is associated with 
better performance on certain hippocampal learning tasks (van Praag et al. 1999; 
Kempermann et al. 2004). More direct evidence that neurogenesis supports 
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hippocampal-dependent learning and memory derives from experiments in which 
depletion of adult-generated neurons impairs specific learning tasks such as 
associative learning and fear conditioning (Shors et al. 2001).  
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3. MATERIALS AND METHODS 
 
3.1. HUMAN NEUROBLASTOMA CELL LINES 
 
3.1.1. Cell cultures 
 
Human neuroblastoma cell lines SH-SY5Y and SKNBE, obtained from 
ATCC (Manassas, VA, USA), were maintained in Dulbecco Modified Eagle 
Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS), 2 mM glutamine and antibiotics (penicillin, 100 U/ml; streptomycin, 100 
µg/ml), in a humidified atmosphere of 5% of CO2 in air at 37 °C. Cell medium 
was replaced every 3 days and the cells were sub-cultured once they reached 90% 
confluence. 
 
 
3.1.2. Plasmids 
 
Human CDKL5 cDNA was kindly provided by Marsha Rich Rosner 
(University of Chicago) (Lin et al. 2005). CDKL5 cDNA was PCR amplified and 
cloned into pCMV14 plasmid (Sigma) in frame with a 3xFLAG C-terminal 
epitope. CDKL5-3xFLAG sequence was subcloned into the bicistronic pIRES2-
EGFP plasmid (Clontech) to obtain a GFP and CDKL5-3xFLAG co-expression 
vector (pGFP/CDKL5-FLAG). 
 
 
3.1.3. Immunocytochemistry 
 
For cell proliferation analyses SH-SY5Y cells were plated onto poly-D-lysine 
coated slides in 6-well plates at density of 3×105 cells per well and transfected 
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with 3 µg of CDKL5-FLAG expression plasmid using lipofectamin (Roche). 
Twenty-four hours after transfection cells were fixed in a 4% paraformaldehyde 
4% sucrose solution at 37 °C for 30 minutes. For immunofluorescence studies the 
following antibodies were used. Primary antibodies: anti-Ki-67 rabbit monoclonal 
(1:100, Thermo Scientific), anti-BrdU rat monoclonal (1:100, AbD Serotec), anti-
cleaved caspase-3 (asp175) rabbit polyclonal (1:100, Cell Signaling Technology), 
anti-β-tubulin III rabbit polyclonal (TubJ, 1:500, Sigma) and anti-FLAG M2 
mouse monoclonal (1:1000; Sigma). Secondary antibodies: FITC-conjugated anti-
rat antibody (1:200, Jackson Immuno Research Laboratories), FITC-conjugated 
anti-rabbit antibody (1:200, Jackson Immuno Research Laboratories), FITC 
conjugated anti-mouse antibody (1:200, Jackson Immuno Research Laboratories) 
and Cy3-conjugated anti-rabbit antibody (1:200, Jackson Immuno Research 
Laboratories). Double immunofluorescence images, taken from random 
microscopic fields (10–12 for each coverslip), were superimposed and used to 
determine the labeling index (LI), defined as percentage of cells co-labeled with: 
anti-BrdU and anti-FLAG or anti-cleaved caspase-3 and anti-FLAG or anti-Ki-67 
and anti-FLAG antibodies. In each experimental condition we randomly analyzed 
a total of 600 cells. Fluorescence images were taken on an Eclipse TE 2000-S 
microscope (Nikon, Tokyo, Japan) equipped with a digital camera Sight DS-
2MBW (Nikon). 
 
 
3.1.4.Western blotting 
 
For the total cell extracts preparation, cells were lysed in RIPA lysis buffer 
(Tris–HCl 50 mM, NaCl 150 mM, Triton X-100 1%, sodium deoxycholate 0.5%, 
SDS 0.1%, protease and phosphatase inhibitors cocktails 1%; Sigma). Cell 
extracts were immediately processed by Western blot or kept frozen (−80 °C) 
until assayed. Sample protein concentration was estimated by the Lowry method 
(Lowry et al. 1951). Equivalent amounts (50 µg) of protein were subjected to 
electrophoresis on a 10% SDS-polyacrylamide gel. The following antibodies were 
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used: anti-CDKL5 (1:500; Sigma) and anti-GADPH (1:5000; Sigma).  
Densitometric analysis of digitized images was performed with Scion Image 
software (Scion Corporation, Frederick, MD, USA) and intensity for each band 
was normalized to the intensity of the corresponding GAPDH band. 
 
 
3.1.5. Analysis of neurite outgrowth 
 
For differentiation analyses neuroblastoma cells were plated onto poly-D-
lysine coated slides in a 24-well plated at density of 2×104 cells per well. After 24 
hours of cell plating, differentiation was induced by retinoic acid (RA; 10 µM) for 
the indicated time. This treatment was replaced each 2 days to replenish RA in 
culture media. Phase contrast photographs of the cultures were taken at various 
time intervals with an Eclipse TE 2000-S microscope (Nikon, Tokyo, Japan) 
equipped with an AxioCam MRm (Zeiss, Oberkochen, Germany) digital camera. 
Ten different areas were randomly selected and neurite outgrowth was measured 
using the image analysis system Image Pro Plus (Media Cybernetics, Silver 
Spring, MD 20910, USA). Only cells with neurites longer than one cell body 
diameter were considered as neurite-bearing cells. All experiments were 
performed at least 3 times. In each experiment we analyzed a total of around 450 
cells. The total length of neurites was divided for the total number of cells counted 
in the areas. 
 
 
3.1.6. Flow cytometric analysis 
 
SH-SY5Y cells were harvested 24 hours after transfection with pGFP or 
pGFP/CDKL5-FLAG plasmids, collected by trypsinization, pelleted and 
resuspended in phosphate buffered saline (PBS) to a final concentration of 1×106 
cells/ml. Transfected cells were then analyzed on a flow cytometer (FACSCalibur, 
Becton Dickinson, San Jose, CA, USA) and sorted by GFP fluorescence 
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(detection filter set at 525 nm). Cell aggregates were gated out, and 10,000 events 
were analyzed. Untransfected SH-SY5Y cells were used to establish a threshold 
for green fluorescence (up to 102 arbitrary fluorescence units in a typical case), 
and which was taken as a threshold for positivity (see Fig. 17C results). For 
differentiation analysis an aliquot of GFP sorted cells was plated in 6-well at the 
density of 3×105 cells per well in the presence or absence of RA (10 µM). For cell 
cycle analysis cells were fixed in 70% ethanol in PBS at −20 °C for at least 1 
hour, washed several times with cold PBS, treated with RNaseA (50 µg/ml) for 30 
minutes at 37 °C and incubated with propidium iodide (30 µg/ml). GFP-positive 
and -negative populations were analyzed separately for DNA content (filter set at 
675 nm) and assigned to specific cell-cycle phases by applying the Cell Quest 
Software (Becton Dickinson, San Jose, CA, USA). 
 
 
3.1.7. Small interfering RNA assay 
 
The siRNA oligonucleotides used for silencing CDKL5 were purchased 
from QIAGEN and were: Hs-CDKL5-5 cat. No:SI02223116 (sense; Si1) and Hs-
CDKL5-10 cat. No:SI004437244 (sense; Si2). Control cells were transfected with 
a scramble siRNA duplex; AllStars Negative Control siRNA (siSCR QIAGEN), 
which does not present homology with any other human mRNAs. SH-SY5Y cells 
were transfected with HiPerFect Transfection Reagent (QIAGEN) with 50 nM 
siRNA (final concentration). For differentiation experiments retinoic acid was 
added to the cells 6 hours post transfection and the cells harvested after further 42 
hours. For proliferation experiments 10 µM BrdU was added to the cells 46 hours 
post transfection and the cells harvested after further 2 hours. 
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3.1.8. Quantitative real time PCR and standard reverse transcription-PCR 
 
RNA samples from cell cultures were prepared using Tri-Reagent (Sigma) 
and treated with DNase (DNA-freeTM; Ambion). Reverse transcription was 
performed using a SuperScript reverse transcription-PCR kit (Invitrogen). Real 
time quantitative PCR (RT-qPCR) was performed using a SYBR Premix Ex Taq 
kit (Takara, Shiga, Japan) and the iQ5 thermocycler (Bio-Rad). The efficiency of 
the used primers was evaluated by calculating the linear regression of Ct data 
points obtained with a series of different primer dilutions and inferring the 
efficiency from the slope of the line. We used the primers that gave efficiency 
close to 100%. Primers used for RT-qPCR are as follows: human CDKL5 
(Cyclin-dependent kinase-like 5) (NM_003159.2) forward, 5’CGGTGGATGTGA 
TGGCAGAAGAC-3’, and reverse 5’GGACTGGAGATTGGACGATGAAGG-
3’; human GUSB (Glucuronidase beta) (NM_000181.3) forward, 5’-AGCGTGG 
AGCAAGACAGTGG-3’, and reverse 5’-ATACAGATAGGCAGGGCGTTCG-
3’. Quantifications were always normalized using endogenous control GUSB. 
 
 
3.2. Cdkl5 KNOCKOUT MICE  
 
3.2.1. Generation of Cdkl5 knockout mice 
 
A 10 kb genomic fragment containing exon 4 of Cdkl5 
(ENSMUSE00000346596) was subcloned into a pDTA targeting plasmid by 
recombineering-mediated transfer from a 178-kb genomic fragment containing the 
C57BL/6J mouse Cdkl5 locus (RP23-213O8, ChoriBACPAC, Oklahoma, CA). A 
loxP site was inserted 806 bp upstream of the exon by recombineering-mediated 
insertion of a loxP- flanked pEM7::kanamycin gene and subsequent Cre 
recombination. An FRT-flanked pEM7/PGK::neomycin selection cassette was 
inserted 347 bp downstream of exon 4. The plasmid was linearized with NruI 
before electroporation into ES cells (129/Sv x C57BL/6N, clone A8, kindly 
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provided by A. Wutz, Wellcome Trust Centre for Stem Cell Research, Stem Cell 
Institute, University of Cambridge). G418-resistent clones were identified and 
screened by long-range PCR. Hybridization with a specific probe for the 5' and 3' 
arms was used to confirm PCR results. Two independent positive ES cell clones 
were injected into C57BL/6N host embryos using a piezo-drill assisted 8-cell 
stage injection procedure developed at the European Molecular Biology 
Laboratory (EMBL, Monterotondo, Italy). Four out of five offspring (all >95% ES 
cell derived) provided germline transmission. Positive offspring were crossed to 
C57BL/6J congenic FLP-deleter mice (Farley et al. 2000) to remove the neomycin 
selection cassette and further crossed to C57BL/6J congenic Cre-deleter mice 
(Tang et al. 2002) to generate the Cdkl5 null allele (see Fig. 18A results). 
 
 
3.2.2. Mouse strains and husbandry 
 
Mice for testing were produced by crossing heterozygous female (-/+) 
Cdkl5 knockout with hemizygous male (-/Y) Cdkl5 knockout mice or with wild-
type male mice (+/Y). Littermate controls were used for all experiments. Animals 
were karyotyped by PCR on genomic DNA using the following primers: 108F: 5’-
ACGATAGAAATAGAGGATCAACCC-3’, 109R: 5’ CCCAAGTATACCCCTT 
TCCA-3’; 125R: 5’-CTGTGACTAGGGGCTAGAGA-3’. The day of birth was 
designed as postnatal day (P) zero and animals with 24 hours of age were 
considered as one-day-old animals (P1). After weaning, mice were housed three 
to five per cage on a 12 h light/dark cycle in a temperature controlled environment 
with food and water provided ad libitum. Experiments were performed in 
accordance with the Italian and European Community law for the use of 
experimental animals and were approved by Bologna University Bioethical 
Committee. In this study all efforts were made to minimize animal suffering and 
to keep the number of animals used to a minimum. 
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3.2.3. Semi-quantitative PCR 
 
Brains from wild-type and Cdkl5 knockout mice aged 2 months were 
collected, washed in PBS-DEPC and one hemisphere was homogenized using an 
automate dounce. Total RNA was extracted using RNeasy Mini Kit (Qiagen, 
Hilden, Germany) and converted into first-strand cDNA (SuperScript II Reverse 
Transcriptase, Invitrogen, Paisley, UK) using oligo-dT according to the 
manufacturer’s protocol. For semiquantitative PCR, DNA was amplified using 
primers against Cdkl5 exons using 1xnPCR Buffer (Promega, Madison, WI), 0.5 
units of Dream Taq (Promega) and 200 mM each dNTPs (Fermentas, Vilnius, 
Lithuania).  
 
 
3.2.4. EEG analysis 
 
Male mice aged 2/4 months were anesthetized with ketamine/xylazine 
supplemented with isofluorane as needed, kept on a heating pad to maintain body 
temperature at 35±1°C, and immobilized in a stereotaxic frame. An incision above 
the skull was cut and burr holes drilled into the skull. Four stainless steel screws 
were used as electrodes placed bilaterally above hippocampus (2.0 mm posterior, 
1.5 mm lateral to bregma) and frontal cortex (1.8 mm anterior, 1.5 mm lateral to 
bregma). Ground and reference screws were anchored on the posterior and middle 
portions of the skull, respectively. A wireless Neurologger 2A recording device 
(400 HZ sampling rate) acquired and stored data in real-time for later 
downloading (Brankack et al. 2010). After surgery animals were housed 
individually and allowed at least one week to recover. Mice were tested in a novel 
cage for a thirty minutes baseline period followed by a 2 hour recording after 
treatment with kainic acid (10 mg/kg and 25 mg/kg, i.p.). Each animal received 
both doses separated by at least one day. Data were downsampled to 200 Hz and 
filtered between 1-25 Hz (Chebyshev I filter, 3rd order). To quantify seizure 
episodes, a Fourier transform (4 s window, 3.5 s overlap, 2 hours period) was 
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applied to the EEG. Seizure events in the 1-8 Hz frequency range were used to 
quantify amplitude The baseline period was used as a cutoff criterion (mean 
power + 8x SD) to define seizure events. 
 
 
3.2.5. Behavior testing  
 
Behavior testing was performed in mice aged 2/4 months. A portion of the 
behavioral data derived from knockout mice containing the neomycin selection 
cassette. No difference in behavior was noted between this allele and the neo-
negative allele and the results were combined. 
 
Clasping - Mice were suspended by their tail for 2 minutes and hind-limb clasping 
was assessed from video recordings. Clasping was defined as present if it 
occurred for more than 5 seconds in an animal. 
 
Home-cage activity - Locomotion was measured using activity-monitoring cages 
similar in size, shape, and material to the home cage (TSE Systems, Bad 
Homburg, Germany). A mouse was placed in the chamber at least 3 hours before 
recording started. Relative activity was monitored continuously for 4 days and 
binned into 12 hour epochs. 
 
Open field - Mice were placed in the center of a 50 x 50 cm open arena equipped 
with video tracking and infrared rearing detection systems (VideoMot2, TSE 
Systems). Cumulative distance travelled was collected in 5 minute intervals for 30 
minutes. 
 
Y-maze spontaneous alternation – Y-Maze Spontaneous Alternation was used for 
measuring the willingness of rodents to explore new environments and 
hippocampus-dependent spatial reference memory. Each mouse was placed at the 
distal part of one arm facing the center of the maze. Each of three arm is 34cm x 5 
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cm x 10 cm height, angled 120° from the others and made of grey opaque plastic. 
After the introduction to the maze, the animal is allowed to freely explore the 
three arms for 8 minutes. Over the course of the multiple arm entries, the subject 
should show a tendency to enter a less recently visit arm. Arm entries were 
defined by the presence of all four-paws in an arm. Each 8 minute trial was 
recorded and scored via ANY-maze videotracking software (Stoelting). The maze 
was washed with 50% ethanol between trials. The percentage of spontaneous 
alternations is defined as: (total alternations / total arm entries-2) x 100. One 
alternation is defined as consecutive entries in three different arms. 
 
 
3.2.6. BrdU injection 
On P40, some animals received for five consecutive days an 
intraperitoneal injection (150 µg/g body weight) of BrdU (5-bromo-2-
deoxyuridine; Sigma) in 0.9% NaCl solution. Animals were sacrificed either 24 
hours after the last BrdU injection (on P45), to examine cell proliferation, or after 
one month (on P75), to examine the fate of the BrdU-labeled cells.  
 
 
3.2.7. Histological procedures 
 
Some animals were deeply anesthetized with ether and transcardially 
perfused with ice cold phosphate-buffered saline (PBS), followed by a 4% 
solution of paraformaldehyde in 100 mM PBS, pH 7.4. Brains were stored in the 
fixative for 24 hours, cut along the midline and kept in 20% sucrose in phosphate 
buffer for an additional twenty-four hours. Hemispheres were frozen and stored at 
-80°C. The right hemisphere was cut with a freezing microtome in 30-µm-thick 
coronal sections that were serially collected in antifreeze solution containing 
sodium azide. Some animals were decapitated and the brain was removed, cut 
along the midline and fixed by immersion in Glyo-Fixx (Thermo Electron Corp., 
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Waltham, MA, USA) for 48 hours. Samples were dehydrated through a series of 
ascending ethanol concentrations, embedded in paraffin, and cut with a microtome 
in ultra-thin sections (4 µm) and mounted on poly-lysine slides.  
Sections from the dentate gyrus (DG) and subventricular zone (SVZ) were 
used for immunohistochemistry. The SVZ of this study corresponds to the rostral 
horn of the lateral ventricle and starts at the rostral pole of the lateral ventricle, 
stretching for 900-1200 µm in the caudal direction. Its rostral and caudal borders 
correspond approximately to +1.18 mm and +0.02 mm planes, respectively, of 
Franklin and Paxinos atlas of the mouse brain. 
 
 
3.2.8. Immunohistochemistry/double-fluorescence immunohistochemistry  
 
One out of six 30-µm-thick coronal sections from the DG and the SVZ of 
animals were processed for immunohistochemistry as previously described 
(Contestabile et al. 2007; Bianchi et al. 2010). Immunohistochemistry was carried 
out on free-floating sections for the frozen brains. For Cdkl5 detection sections 
were incubated overnight at 4°C with rabbit anti-Cdkl5 antibody (1:250, Sigma-
Aldrich) and for 2 hours with a Cy3 conjugated anti-rabbit IgG (1:200; Jackson 
Immunoresearch). For BrdU immunohistochemistry sections were denatured in 2 
N HCl for 30 minutes at 37°C and incubated overnight at 4°C with a primary 
antibody anti-BrdU (mouse monoclonal 1:100, Roche Applied Science, 
Mannheim, Germany). Detection was performed with a Cy3-conjugated anti-
mouse secondary antibody (1:200; Jackson Immunoresearch). For Ki-67 
immunohistochemistry sections were incubated overnight at 4°C with rabbit 
monoclonal anti-Ki67 antibody (1: 200; Thermo Scientific Neumarkers, Fremont, 
CA. USA) and for 2 hours with a Cy3 conjugated anti-rabbit IgG (1:200; Jackson 
Immunoresearch). For cleaved caspase-3 immunohistochemistry, sections were 
incubated overnight at 4°C with a rabbit cleaved caspase-3 antibody (1:100; Cell 
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Signaling Technology) and for 2 hours with an HRP-conjugated anti-rabbit 
secondary antibody (dilution 1:200; Jackson Immunoresearch). Detection was 
performed using the TSA Cyanine 3 Plus Evaluation Kit (Perkin Elmer). For 
Synaptophysin immunohistochemistry, sections from the DG were incubated for 
48 hours at 4°C with mouse monoclonal anti-SYN (SY38) antibody (1:1000, 
Millipore Bioscience Research Reagents) and for two hours with a Cy3 
conjugated anti-mouse IgG secondary antibody (1:200; Jackson Immunoresearch). 
For DCX immunohistochemistry sections from the DG were incubated overnight 
at 4°C with a goat polyclonal anti-DCX antibody (1:100; Santa Cruz 
Biotechnology). Sections were then incubated for 2 hours at room temperature 
with a biotinylated anti-goat IgG secondary antibody (1:200; Vector Laboratories) 
and thereafter incubated for 1 hour with VECTASTAIN® ABC kit (Vector 
Laboratories). Detection was performed using DAB kit (Vector Laboratories). For 
double-fluorescence immunostaining, sections were incubated overnight at 4°C 
with a primary antibody, rat monoclonal anti-BrdU antibody (1:100; AbD Serotec, 
Kidlington, Oxford, UK) and one of the following primary antibodies: i) mouse 
monoclonal anti NeuN (1:250; Chemicon, Billerica, MA, USA) and ii) mouse 
monoclonal anti-glial fibrillary acidic protein (GFAP) (1:400; Sigma). Sections 
were then incubated with a Cy3 conjugated anti-rat IgG (1:100; Jackson 
Immunoresearch) secondary fluorescent antibody, for BrdU immunoistochemistry 
and FITC conjugated anti-mouse IgG (1:100; Sigma-Aldrich) for NeuN or GFAP 
immunoistochemistry. Fluorescent images were taken with an Eclipse TE 2000-S 
microscope (Nikon, Tokyo, Japan) equipped with an AxioCam MRm (Zeiss, 
Oberkochen, Germany) digital camera or with a Leica TCS confocal microscope 
(Leica Microsystems, Wetzlar, Germany).  
 
Ultra-thin consecutive sections were deparaffinized, incubated with a goat 
anti-DCX antibody (1:100; Santa Cruz Biotechnology) or with a rabbit cleaved 
caspase-3 antibody (1:200; Cell Signaling Technology). Detection was performed 
with a HRP-conjugated anti-goat or anti-rabbit secondary antibody (dilution 
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1:200; Jackson Immunoresearch, West Grove, PE, USA) and DAB kit (Vector 
Laboratories, Burlingame, CA, USA). 
 
3.2.9. Measurements 
 
Cell counting - The total number of positive cells (BrdU, Ki-67, NeuN/BrdU, 
GFAP/BrdU, cleaved caspase-3, DCX) was estimated by multiplying the number 
counted in the series of sampled sections by the inverse of the section sampling 
fraction (section sampling fraction = 1/6). 
 
Stereology of the DG - In the series of Hoechst-stained sections, the volume of the 
granule cell layer was estimated as previously described (Contestabile et al. 2007; 
Bianchi et al. 2010) by multiplying the sum of the cross sectional areas by the 
spacing T between sampled sections. Granule cell numerical density was 
determined using the optical fractionators (Bianchi et al. 2010). Counting frames 
with a side length of 30 µm and a height of 8 µm spaced in a 150 µm square grid 
(fractionator) were systematically used. The total number of granule cells was 
estimated as the product of the volume of the granule cell layer and the numerical 
density. 
 
Measurement of the dendritic tree - Dendritic trees of DCX-positive granule cells 
of the DG were traced with a dedicated software, custom-designed for dendritic 
reconstruction (Immagini Computer, Milan, Italy), interfaced with Image Pro Plus 
(Media Cybernetics, Silver Spring, MD 20910, USA). The dendritic tree was 
traced live, at a final magnification of 500x, by focusing into the depth of the 
section. The operator starts with branches emerging from the cell soma and after 
having drawn the first parent branch goes on with all daughter branches of the 
next order in a centrifugal direction. At the end of tracing the program 
reconstructs the number and length of individual branches, the mean length of 
branches of each order and total dendritic length.  
77 
 
Connectivity in the molecular layer of the DG – To evaluate the connectivity in 
the molecular layer of the DG, intensity of SYN immunoreactivity (IR) was 
determined by optical densitometry of immunohistochemically stained sections. 
Fluorescence images were captured using a Nikon Eclipse E600 microscope 
equipped with a Nikon Digital Camera DXM1200 (ATI system). Densitometric 
analysis of SYN in the inner (I), middle (M) and outer (O) third of the molecular 
layer was carried out using Nis-Elements Software 3.21.03 (Nikon). For each 
image, the intensity threshold was estimated by analyzing the distribution of pixel 
intensities in the image areas that did not contain IR. This value was then 
subtracted to calculate IR of each sampled area. 
 
 
3.2.10. Western blotting  
 
For the preparation of total brain extracts mice aged 2 months were 
decapitated and brain rapidly collected on ice. One hemisphere was homogenized 
in lysis buffer (50 mM HEPES pH 7.0, 250 mM NaCl, 0.5% NP-40, 5 mM 
EDTA, 1 mM DTT, protease/phosphatase inhibitor mix composed of 0.5 mM 
Na3VO4, 0.5 mM PMSF, protease inhibitor mixture (Roche Applied Sciences, 
Monza, Italy), using an automated dounce. For the preparation of hippocampal 
extracts from P19 mice, tissues were homogenized in RIPA buffer (Tris-HCl, 50 
m M, NaCl 150 mM. Triton X-100 1%, SDS, 0,1%, sodium deoxycholate 0,5%, 
PMSF 1mM, protease and phosphatase inhibitors cock-tails, 1%). Extracts were 
immediately processed by Western blot or kept frozen (-80°C) until assayed. 
Sample protein concentration was estimated by the Lowry method (Lowry et al. 
1951). Equivalent amounts (50 µg) of protein were subjected to electrophoresis on 
a 10% SDS-polyacrylamide gel and incubated with the following antibodies: anti-
CDKL5 (1:500), anti-GAPDH (1:5000), anti-tubulin (1:5000) (Sigma) anti-
phosphorylated Erk1/2 (1:1000), anti Erk1/2 (1:1000), anti-phospho-AKT-Ser473 
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(1:1000), anti-phospho-AKT-Thr308 (1:1000), anti-AKT (1:1000), anti-phospho-
GSK3-β-Ser9 (1:1000), anti-GSK3-β (1:1000), anti-phospho-CRMP2 Thr514 
(1:1000), anti-CRMP2 (1:1000) (Cell Signaling Technology); anti β-catenin 
(1:1000; BD Transduction Laboratories); anti-phospho-CREB-Ser133 (1:1000) 
and anti-CREB (1:1000) (Upstate Biotechnology) overnight at 4 C, incubated 
with secondary antibodies (one hour at room temperature) and developed using 
ECL detection (GE Healthcare, Chalfont St. Giles, UK). Densitometric analysis of 
digitized images was performed with Scion Image software (Scion Corporation, 
Frederick, MD, USA) and intensity for each band was normalized to the intensity 
of the respective total protein levels, tubulin or GAPDH band. 
 
 
3.3. NPC cultures 
 
3.3.1. NPC cultures and treatments 
 
Cells were isolated from the subventricular zone (SVZ) of newborn (P1-
P2) homozygous (-/-), heterozygous (-/+) and wild-type (+/+) female Cdkl5 
knockout mice. To obtain neurospheres, cells were cultured in suspension in 
DMEM/F12 (1:1) containing B27 supplements (2%), FGF-2 (20 ng/mL), EGF (20 
ng/mL), heparin (5 µg/mL), penicillin (100 units/mL), and antibiotics, as 
previously reported (Trazzi et al. 2011). Primary neurospheres were dissociated at 
day 7-8 using Accutase (PAA, Pasching, Austria) to derive secondary 
neurospheres. The sub-culturing protocol consisted of neurosphere passaging 
every 7 days with whole culture media change (with freshly added FGF-2 and 
EGF). All experiments were done using neurospheres obtained after 1-3 passages 
from the initially prepared cultures. Cell cultures were kept in a 5% CO2 
humidified atmosphere at 37°C. 2mM Lithium chloride (Sigma) was 
administrated on alternate days. 
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3.3.2. Viral Particles Transduction 
 
NPCs were infected, at day 1 post-plating, with CDKL5 Adenovirus 
Particles (Vector BioLabs) or GFP Adenovirus Particles (Vector BioLabs) at 100 
multiplicities of infection (MOI).  
 
 
3.3.3. BrdU immunocytochemistry 
 
For proliferation analysis dissociated neurospheres were cultured for 3 
days, treated with 10 µM BrdU for additional 16 hours and harvested on 
microscope slides by cytospin centrifugation (215 x g, 5 min, Shandon, Thermo, 
Dreieich, Germany). Specimens, processed as previously described (Contestabile 
et al. 2009), were incubated with a mouse anti-5-bromo-2-deoxyuridine (BrdU) 
monoclonal antibody (1:100; Roche Applied Science) and a Cy3-conjugated anti-
mouse secondary antibody (1:200; Sigma). Samples were counterstained with 
Hoechst-33258.  
 
 
3.3.4. In vitro differentiation, immunocytochemistry and analysis of neurite 
length.  
 
Neurospheres were dissociated into a single cell suspension and plated 
onto poly-L-ornithyine-coated 24-well chamber slides at a density of 3×104 cells 
per well. Cells were cultured for 2 days in DMEM/F12 medium containing EGF 
(20 ng/mL), FGF (20 ng/mL) and 2% fetal bovine serum (FBS) and then 
transferred to differentiation medium (EGF and FGF free plus 1% FBS) for 6 or 
12 days. Every 2 days half of the medium was replaced with fresh differentiation 
medium. For immunofluorescent staining, differentiated NPC cultures were 
paraformaldehyde-fixed and stained with antibodies against: GFAP (1:400; 
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Sigma) and β-tubulin III (1:100; Sigma) as primary antibodies, and with mouse 
FITC-conjugated (1:200; Sigma) and rabbit Cy3-conjugated (1:200; Jackson 
Laboratories), as secondary antibodies. Samples were counterstained with 
Hoechst-33258. Ten random fields from each coverslip were photographed and 
counted. The number of positive cells for each marker was referred to the total 
number of Hoechst-stained nuclei. Evaluation of neurite length was performed by 
using the image analysis system Image Pro Plus (Media Cybernetics, Silver 
Spring, MD 20910, USA). The average neurite length per cell was calculated by 
dividing the total neurite length by the number of cells counted in the areas. 
 
 
3.3.5. Western blotting 
 
Total proteins from neurosphere cultures of Cdkl5 knockout and wild-type 
mice were homogenized in ice-cold RIPA buffer (50 mM Tris-HCl pH 7.4, 150 
mM NaCl, 1% Triton-X100, 0.5% sodium deoxycholate,0.1 % SDS) 
supplemented with 1mM PMSF and 1% proteases and phosphatases inhibitor 
cocktail (Sigma). Protein concentration was determined by the Lowry method 
(Lowry et al. 1951). Equivalent amounts (50 µg) of protein were subjected to 
electrophoresis on a 4-12% Mini-PROTEAN® TGX™ Gel (Bio-Rad) and 
transferred to a Hybond ECL nitrocellulose membrane (Amersham Life Science). 
The following primary antibodies were used: anti-CDKL5 (1:500), anti-GAPDH 
(1:5000) (Sigma), anti-phospho-AKT-Ser473 (1:1000), anti-AKT (1:1000), anti-
phospho-GSK3-β-Ser9 (1:1000) and anti-GSK3-β (1:1000) (Cell Signaling 
Technology). Densitometric analysis of digitized images was performed with 
Scion Image software (Scion Corporation, Frederick, MD, USA) and intensity for 
each band was normalized to the intensity of the respective total protein levels or 
GAPDH band. 
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3.4. Statistical analysis 
 
Results are presented as the mean ± standard error (SE) of the mean. 
Statistical significance was assessed by two-way analysis of variance (ANOVA), 
followed by Duncan's post hoc test or by the two-tailed Student’s t-test A 
probability level of P<0.05 was considered to be statistically significant. 
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4. RESULTS 
 
Despite the clear involvement of CDKL5 mutations in intellectual 
disability, the function/s of CDKL5 and particularly its role in the development of 
the nervous system are still poorly understood. Several studies in rodents have 
shown that Cdkl5 is highly expressed in the developing brain (Rusconi et al. 2008; 
Chen et al. 2010), suggesting an important role of CDKL5 in neuronal maturation.  
In order to elucidate the role of CDKL5 on neuronal maturation we used, 
as an in vitro neuronal model, human neuroblastoma cell lines. Human 
neuroblastoma cell lines show several biochemical and functional features of 
neurons and are considered a good in vitro model of neurons, as they can be 
induced to differentiate upon treatment with retinoic acid (RA) (Melino et al. 
1997; Singh and Kaur 2007). For these reasons neuroblastoma cells have been 
here employed to study the CDKL5 function in vitro. 
In parallel we created a Cdkl5 knockout (KO) mouse model in 
collaboration with the European Molecular Biology Laboratory (EMBL), 
Monterotondo, Italy. In the current study we performed a first behavioral 
characterization on the Cdkl5 KO mouse. In rodents, the hippocampal dentate 
gyrus produces its neurons mainly postnatally (Altman and Bayer 1990). This 
makes the hippocampus an ideal structure in order to examine the role of Cdkl5 
on fundamental neurodevelopmental processes such as neurogenesis and dendritic 
development. In the current study we used a Cdkl5 KO mouse model in order to 
dissect the role of CDKL5 on hippocampal development and to establish the 
mechanism/s underlying its actions.  
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4.1. CDKL5 enhances neuronal differentiation in the SH-SY5Y 
neuroblastoma cell line 
 
 
We first sought to establish whether human neuroblastoma cell lines 
exhibit a positive correlation between CDKL5 expression and neuronal 
differentiation similar to those observed in vivo during brain development 
(Rusconi et al. 2008; Chen et al. 2010).  
 
We evaluated morphological differentiation and CDKL5 expression in two 
neuroblastoma cell lines, SH-SY5Y and SKNBE, following RA treatment. Within 
3 days of treatment with RA, SH-SY5Y cells present long branched processes 
measuring up to 5–6 fold the length of the cell body (Fig. 15A,B). Consistent with 
previous studies (Ciani et al. 2004), SKNBE cells were still undifferentiated after 
3 days of treatment and RA-mediated differentiation started only after 7 days from 
RA exposure (Fig. 15A,B). Although basal CDKL5 expression was notably higher 
in untreated SH-SY5Y than in untreated SKNBE cells (Fig. 15C), differentiating 
SH-SY5Y cells exhibited strong up-regulation of CDKL5 expression (Fig. 15C), 
whereas SKNBE cells did not show any change in CDKL5 expression within the 
same RA-treatment period (Fig. 15C).  
 
The up-regulation of CDKL5 expression in differentiating RA-treated SH-
SY5Y cells was further confirmed at the protein level (Fig. 15D). We found that 
CDKL5 expression increased significantly in this cell line after 3 (+40%) and 7 
(+100%) days of RA exposure (Fig. 15D).  
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Figure 15 CDKL5 expression during differentiation in neuroblastoma cell 
lines. 
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(A) Immunofluorescence images showing the morphology of SH-SY5Y (left 
panel) and SKNBE (right panel) cells after 7 days of treatment with (+RA) 
or without (−RA) retinoic acid. Cells were stained for β-tubulin III (green) 
and nuclei were counterstained with Hoechst dye (blue). Scale bar: 30 µm.  
 
(B) Quantification of neurite outgrowth of SH-SY5Y (left histogram) and 
SKNBE (right histogram) cells that were either untreated or treated with RA 
(10 µM) for 3 and 7 days. Neurite outgrowth was expressed as mean neurite 
length (µm) per cell. Data are expressed as mean±SE of 4 independent 
experiments. A minimum of 400 cells were evaluated in each experiment for 
each condition. *P<0.05; ***P<0.001, treated vs. untreated condition 
(Duncan's test after ANOVA). 
 
(C) Quantification by RT-qPCR of CDKL5 expression in SH-SY5Y and 
SKNBE cells that were either untreated or treated with RA (10 µM) for 3 or 
7 days. Data, given as percentage of untreated SH-SY5Y cells, are expressed 
as mean±SE. The asterisks indicate a significant difference between treated 
vs. untreated condition, *P<0.05, ***P<0.001 (Duncan’s test after ANOVA)  
 
(D) CDKL5 protein expression in SH-SY5Y cells either untreated or treated 
with RA (10 µM) for 3 and 7 days was analyzed by western blot with a 
CDKL5 specific antibody.  
 
 
 
The positive correlation between CDKL5 expression and SH-SY5Y 
differentiation indicates that SH-SY5Y neuroblastoma cells may represent a 
suitable model to study the role of CDKL5 in neuronal differentiation. 
 
 
To further investigate the role of CDKL5 in neuronal differentiation, we 
over-expressed CDKL5 in SH-SY5Y cells by transient transfection of a 
pGFP/CDKL5-FLAG expression vector. We compared neuritic outgrowth in 
GFP- and GFP-CDKL5-positive cells isolated by cell sorting 24 hours after 
transfection and then grown for 1–2 days either in the absence or presence of RA. 
We found that CDKL5 was able to induce a beginning differentiation also in the 
absence of RA treatment. While cells expressing GFP alone (controls) 
occasionally emitted very short processes (Fig. 16B, left panel), cells over-
expressing CDKL5 had longer processes with a length increase by +100% after 2 
86 
 
days in culture (Fig. 16A,B, left panel), indicating that CDKL5 is able to promote 
differentiation also in the absence of pro-differenziative stimuli such as RA 
treatment. To investigate the effects of CDKL5 over-expression also on RA-
induced differentiation, GFP- and GFP-CDKL5-tranfected cells were cultured for 
1–2 days in the presence of RA (Fig. 16A,B). After 1 day of RA treatment, 
CDKL5 expressing cells exhibited a greater neurite length compared to control 
cells (+30%, Fig. 16A,B), but this difference was no longer detectable after 2 days 
of RA treatment (Fig. 16A,B).  
 
These data clearly show that CDKL5 can promote neuronal 
differentiation also in the absence of pro-differentiative stimuli and enhances 
RA-induced differentiation in SH-SY5Y neuroblastoma cells.  
 
 
To further confirm this finding, we tested whether a reduction in CDKL5 
expression interfered with RA-induced differentiation. To this purpose, SH-SY5Y 
cells were transfected with two different siRNAs against CDKL5 (si1, si2) to 
inhibit CDKL5 expression and treated with RA. After 48 hours of treatment, the 
reduced expression of CDKL5 induced by the siRNAs against CDKL5 (−45% and 
−60%, Fig. 16C), confirmed by western blot analysis, was paralleled by a 
significant reduction (−46% and −58%, Fig. 16C) in neurite outgrowth.  
Transfection with a scrambled siRNA (siScr), as negative control, had no effect 
on CDKL5 expression and RA induced cell differentiation (Fig. 16C,D), to further 
confirm the role of CDKL5 on differentiation of SH-SY5Y cells. 
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Figure 16 CDKL5 induces differentiation in the SH-SY5Y neuroblastoma 
cell line.  
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(A) Quantification of neurite outgrowth of SH-SY5Y cells transfected with 
either GFP-CDKL5 or GFP. Twenty-four hours from transfection, cells were 
FACS sorted for GFP fluorescence and cultured for 1–2 days with or 
without retinoic acid (RA; 10 µM). Neurite elongation was expressed as 
mean neurite length (µm) per cell. Data are expressed as mean±SE of 3–4 
independent experiments. A minimum of 400 cells were evaluated in each 
experiment for each condition. The asterisks indicate a significant difference 
between cells expressing GFP-CDKL5 vs. cells expressing GFP alone. 
***P<0.001; two-tailed t-test.  
 
(B) Representative phase-contrast images of cells expressing GFP-CDKL5 
or GFP and cultured for 1 or 2 days in absence (RA-) or in presence of 10 
µM RA (RA+). Scale bar: 15 µm.  
 
(C) SH-SY5Y cells were transfected with two different siRNAs against 
CDKL5 (si1 and si2; 50 nM) or with scramble siRNA (siScr; 50 nM). 
Quantification by western blots of CDKL5 expression was performed 48 
hours after transfection. Data are expressed as mean±SE of 3 independent 
experiments. **P<0.01; ***P<0.001; two-tailed t-test. 
 
(D) Quantification of neurite outgrowth of SH-SY5Y cells transfected with 
si1, si2 or siSCR (50 nM). Six hours after siRNA transfection cells were 
treated with RA (10 µM) and analyzed 42 hours later for neurite outgrowth. 
Data are expressed as mean±SE of 3 independent experiments. **P<0.01; 
***P<0.001; two-tailed t-test. 
 
 
 
 
4.2. CDKL5 negatively regulates cell proliferation in the SH-SY5Y 
neuroblastoma cell line by blocking cell cycle progression 
 
CDKL5 expression peaks during late embryonic stage and the first 
postnatal period (Chen et al. 2010), when most of the neuronal progenitors stop 
proliferating and enter the differentiated state, suggesting that it may negatively 
control neuron proliferation.  
To address this point, SH-SY5Y cells transiently expressing the CDKL5-
FLAG fusion protein were evaluated for proliferation rate by a 
bromodeoxyuridine (BrdU) incorporation assay, in which the thymidine analogue 
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is incorporated into DNA during the S-phase of the cell cycle. The effect of 
CDKL5 over-expression on cell proliferation was determined by evaluating the 
number of proliferating cells (BrdU positive cells) that expressed CDKL5 
(CDKL5-FLAG positive cells). Interestingly, we never found cells that, in 
addition to express CDKL5, were also BrdU positive, supporting our hypothesis 
that CDKL5 may inhibit cell proliferation (Fig. 17A). Similar results were 
obtained with a second proliferation marker, Ki-67, which is expressed in dividing 
cells through late-G1+S+G2+M but not G0 and early G1 phases of cell cycle. As 
expected no CDKL5-positive cells were also positive for Ki-67 (data not shown).  
 
This data indicate that CDKL5 over-expression specifically blocks cell 
proliferation of neuroblastoma cells.  
 
 
To further confirm the anti-proliferative role of CDKL5 in neuroblastoma 
cells, we silenced the endogenous expression of CDKL5 using two siRNAs 
directed against CDKL5 (si1, si2) and evaluated the effect on proliferation by 
BrdU-immunostaining. A reduced expression of CDKL5 after siRNAs 
transfection was accompanied by a significant increase in cell proliferation (+31% 
si1, +39% si2, Fig. 17B), while treatment with a scrambled siRNA (siScr), as 
negative control, had no effect on cell proliferation (data not shown). These data 
support the idea that CDKL5 can inhibit cell proliferation. 
 
 
The hypothesis that CDKL5 can inhibit proliferation leads us to speculate 
that CDKL5 may affect the cell cycle dynamics. To clarify this point, we 
compared the cell cycle profile of GFP vs. GFP-CDKL5 transfected SH-SY5Y 
cells. FACS sorted GFP and GFP-CDKL5 positive cells (Fig. 17C) were treated 
with propidium iodide to stain DNA and analyzed by flow cytometry. We found 
that the fraction of cells in G0/G1 was significantly increased in CDKL5 over-
expressing cells as compared to control cells and, as a consequence, the fraction of 
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S phase cells was decreased. In CDKL5 over-expressing cells, the percentage of 
G0/G1 became approximately 70%, suggesting that CDKL5 blocks cells in G0/G1 
phase (Fig. 17D). We found no differences in the percentage of cells in the sub-
G1, which is considered to indicate the proportion of apoptotic cells over total, 
indicating that CDKL5 does not induce apoptosis in neuroblastoma cells. To 
further confirm that CDKL5 over-expression does not induce apoptotic cell death 
in this cell line, we performed an immunostaining for intracellular cleaved-
caspase-3 and found no differences between CDKL5 positive and negative cells 
(Fig. 17E).  
 
These data clearly show that CDKL5 over-expression does not induce 
apoptotic cell death in human neuroblastoma cells and that the inhibition of cell 
proliferation is due to an arrest in the G0/G1 phase of the cell cycle. 
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Figure 17 CDKL5 negatively regulates proliferation in SH-SY5Y 
neuroblastoma cell lines by blocking cell cycle progression. 
 
(A) Immunofluorescence images of SH-SY5Y neuroblastoma cells transfected 
with CDKL5-FLAG. Twenty-four hours after transfection, SH-SY5Y cells 
were treated with BrdU (10 µM) for 2 hours and thereafter cells were 
processed for double immunocytochemistry. Cells were immunostained for 
FLAG (red signal) and BrdU (green signal) and cell nuclei were 
counterstained with Hoechst dye (blue signal). The arrows in Hoechst and 
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merge images indicate the nuclei of cells expressing exogenous CDKL5. 
Three independent experiments were performed and a minimum of 600 cells 
were evaluated in each experiment for each condition. Scale bar: 20 µm. 
 
(B) Labeling index (LI), defined as percentage of BrdU positive cells over 
total cell number, was determined for SH-SY5Y transfected with two 
different siRNAs against CDKL5 (si1 and si2; 50 nM) or with scramble 
siRNA (siSCR; 50 nM). Forty-six hours after transfection cells were exposed 
to BrdU (10 µM) for the last 2 hours. Data, given as percentage of control 
condition, are expressed as mean±SE of 3 independent experiments. 
**P<0.01; two-tailed t-test.  
 
(C) Twenty-four hours after transfection with GFP-CDKL5 or GFP alone, 
SH-SY5Y cells were FACS sorted for GFP expression. The threshold for 
positivity for GFP was established as the levels corresponding to 
untransfected cells (histogram on the left). The green area in the histogram 
on the right shows fluorescence intensity of sorted GFP-CDKL5 positive 
cells.  
 
(D) Distribution of cell populations in the G0/1, S, or G2/M phases of the cell 
cycle, identified by flow cytometry analysis. Data, given as percentage of 
either GFP-CDKL5 or GFP cells in each phase of the cell cycle, are 
expressed as mean±SE of 3 independent experiments, *P<0.05, **P<0.01, 
two-tailed t-test. 
 
(E) Immunofluorescence image of cleaved caspase-3 immunostainig of SH-
SY5Y neuroblastoma cells transfected with GFP-CDKL5. Twenty-four hours 
after transfection, SH-SY5Y cells were immunostained for cleaved caspase-3 
(red signal), CDKL5 (green signal) and cell nuclei were counterstained with 
Hoechst dye (blue signal). Scale bar: 25 µm.  
Percentage of cleaved caspase-3-positive cells over total number of GFP-
CDKL5-positive cells and GFP-positive cells (histogram on the right). Data 
are expressed as mean±SE of 3 independent experiments. A minimum of 450 
cells were evaluated in each experiment for each condition. 
 
 
These results demonstrate that CDKL5 affects both neurite growth and 
cell proliferation, suggesting that CDKL5 may modulate not only dendritic 
maturation but also cell proliferation in the developing brain.  
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4.3. Creation and validation of Cdkl5 conditional knockout mice  
 
A constitutive knockout allele of Cdkl5 was produced by germline deletion 
of exon 4 of a Cdkl5 conditional knockout allele produced by standard gene 
targeting in embryonic stem cells (Fig. 18A). Since Cdkl5 is localized on X 
chromosome, the genotypes deriving from deletion of the Cdkl5 gene are: 
homozygous females (-/-), heterozygous female (+/-) and hemizygous males (-
/Y). Semi-quantitative PCR on total brain RNA from female wild-type (+/+), 
heterozygous (+/-) and homozygous (-/-) Cdkl5 knockout (KO) mice with primers 
spanning exons confirmed the absence of exon 4, but normal levels of exon 2,3 
and 5 in Cdkl5 KO female mice (Fig. 18B). To confirm the absence of the full-
length Cdkl5 protein we performed western blot analysis on whole brain extracts 
using a specific antibody against CDKL5. As shown in Fig. 18C hemizygous male 
(-/Y) and homozygous female (-/-) Cdkl5 KO mice do not express the protein, 
while heterozygous females (-/X) show intermediate levels of Cdkl5 expression. 
The absence of the Cdkl5 protein in mutant mice was further confirmed by 
immunofluorescence analysis of CA1 hippocampus brain sections (Fig. 18D). 
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Figure 18 Generation and validation of Cdkl5 conditional knockout mice. 
 
(A) Genomic organization of the Cdkl5 locus showing critical exon 4 
(ENSMUSE00000346596), the targeting construct, successfully targeted 
Cdkl5 locus (genotyping primers indicated by arrows), FRT-deleted 
conditional Cdkl5 knockout allele, and Cre-deleted constitutive Cdkl5 
knockout allele used in the present study.  
 
(B) Semi-quantitative PCR on total brain RNA from female wild-type (+/+), 
heterozygous (+/-) and homozygous (-/-) Cdkl5 KO mice with primers 
spanning exons confirmed an absence of exon 4, but normal levels of exon 
2,3 and 5 in Cdkl5 mutant female mice.  
 
(C) Western blot analysis of whole brain protein extracts of wild-type (+/+), 
heterozygous (+/-), and homozygous (-/-) female Cdkl5 KO mice and wild-
type (+/Y) and hemizygous (-/Y) male Cdkl5 KO mice using a polyclonal 
anti-Cdkl5 antibody confirm the absence of Cdkl5 in homozygous female (-/-
) and hemizygous male (-/Y) mutant mice, while heterozygous females (+/-) 
show intermediate levels of Cdkl5 expression. 
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(D) Examples of CA1 hippocampus brain sections from adult male wild-type 
(WT) and Cdkl5 knockout (KO) mice processed for fluorescent 
immunostaining for CDKL5 (red signal). Cell nuclei were counterstained 
with Hoechst dye (DAPI- blue signal). Scale bar: 40 µm. 
 
 
 
 
 
4.4. Behavioral impairments in Cdkl5 knockout mice  
 
A first characterization of the Cdkl5 mutant mice show that heterozygous 
(+/-) and homozygous females (-/-), as well as hemizygous male (-/Y) Cdkl5 KO 
mice had no differences in viability, body weight (Fig. 19A), and absolute as well 
as relative brain weight compared to wild-type littermates (data not shown; Fig. 
19B). 
 
In order to identify behavioral features that mimic the clinical features 
described in CDKL5 disorder, including seizures, motor abnormalities and 
impaired hippocampal-dependent learning and memory, we performed a general 
behavioral screen (Rogers et al. 1999) on Cdkl5 mutant mice. 
 
We first evaluated clasping of hind-limbs and observed that a significant 
fraction of heterozygous (+/-) and homozygous female (-/-) as well as hemizygous 
male (-/Y) Cdkl5 KO mice revealed abnormal clasping of hind-limbs compared to 
wild-type littermates (Fig. 19C,D).  
Continuous monitoring of home cage activity showed a significant 
decrease in locomotion in both homozygous female (-/-) and hemizygous male (-
/Y) Cdkl5 KO mice and intermediate levels in heterozygous (+/-) Cdkl5 KO 
females (Fig 19E,F). Hypolocomotion was not seen when mice were placed in a 
novel open arena (data not shown), suggesting that the deficit did not reflect a 
reduced capacity for locomotion. 
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Figure 19 Behavioral impairments in the Cdkl5 knockout mice. 
 
(A) Histogram showing body weight (expressed in grams) of 6 weeks old 
wild-type an Cdkl5 KO mice. No differences in body weight was observed in 
heterozygous (+/-) and homozygous (-/-) female Cdkl5 KO mice, as well as 
hemizyous (-/Y) male KO mice compared to sex-matched wild-type 
littermates.  
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(B) Representative images of dissected brains from wild-type (+/+), 
heterozygous (+/-) and homozygous (-/-) female Cdkl5 KO mice. No 
differences in brain size and brain weight were observed in female Cdkl5 
KO mice compared to wild-type littermates.  
 
(C-D) Percentage of mice showing hind-limb clasping was significantly 
increased in adult female and male Cdkl5 KO mice (+/+, n = 28; +/-, n = 
38; -/-, n = 32; +/Y, n = 55; -/Y, n =42). Data are expressed as 
mean±SE,**P<0.01, ***P<0.001; two-tailed t-test.  
 
(E-F) Home cage activity was significantly decreased in adult female (E) 
and male (F) Cdkl5 KO mice. Data are expressed as mean±SE,***P<0.001; 
two-tailed t-test;  
 
 
 
 
Although early onset seizures are one of the prominent features of the 
CDKL5 disorder, we surprisingly found no evidence for spontaneous seizures 
during videotaped observations of adult Cdkl5 KO mice either in the home cage 
or following transfer to a novel cage (data not shown). Electroencephalographic 
(EEG) recordings from implanted surface electrodes in freely behaving animals 
did not reveal spontaneous epileptiform activity in hemizygous (-/Y) male Cdkl5 
KO mice (Fig. 20A,B left panel).  
 
 
Pharmacological induction of seizures with kainic acid was monitored by 
surface EEG. Low dose kainic acid did not induce overt seizures, but caused 
occasional epileptiform activity patterns in both hemizygous (-/Y) Cdkl5 male KO 
mice and wild-type (+/Y) littermates (data not shown). At the higher dose, kainic 
acid induced overt seizures, as evidenced by periods of sudden immobility and in 
some cases tonic clonic convulsions in both hemizygous (-/Y) Cdkl5 KO and 
wild-type (+/Y) littermate mice. Correspondingly, prominent epileptiform activity 
bursts were observed in the EEG of both genotypes (Fig. 20A,B right pannel). 
Cdkl5 KO mice did not differ from wild-type littermates in latency to epileptiform 
activity bursts suggesting similar susceptibility to the drug (Fig. 20C). However, 
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the mean duration of high-amplitude bursts was longer and the frequency lower in 
Cdkl5 KO mice compared to wild-type littermates (Fig. 20D,E). Power spectrum 
analysis revealed a significant dose-dependent increase in low frequency EEG 
power in wild-type, but not in hemizygous (-/Y) Cdkl5 male KO mice treated with 
kainic acid when compared to baseline (Fig. 20F,G).  
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Figure 20 Altered seizure response in Cdkl5 knockout mice.  
 
(A-B) Representative electroencephalogram (EEG) traces recorded from 
surface electrodes placed over the somatosensory cortex in freely moving 
male wild-type (+/Y) and Cdkl5 KO (-/Y) mice. (Left) Baseline EEG before 
drug treatment. (Right) EEG taken during 2 hour post-injection period 
following treatment with high dose (25 mg/kg, i.p.) kainic acid. (expanded 
trace) Detail of epileptiform event showing low frequency, high amplitude 
activity.  
 
(C-E) Latency (C) to the first epileptiform event did not differ between wild-
type (+/Y) and Cdkl5 KO (-/Y) male mice, but (D) mean duration of events 
was longer (p=0.058) and (E) mean frequency was lower in hemizygous (-
/Y) male Cdkl5 KO mice (+/Y: n = 4, -/Y: n= 5). Data are expressed as 
mean±SE, *P<0.05; two-tailed t-test. 
 
(F-G) Average EEG power spectra of (left) baseline and (right) post-
injection periods for (F) low dose (10 mg/kg, i.p.) and (G) high dose (25 
mg/kg, i.p.) kainic acid treatment revealed a significant, dose-dependent 
increased in low frequency EEG power in wild-type, but not Cdkl5 KO mice. 
 
 
 
 
In order to examine hippocampal-dependent learning and memory in 
Cdkl5 KO mice, we evaluated hippocampus-dependent spatial working memory 
by using the Y-maze paradigm. We found that while wild-type mice entered more 
frequently into the novel, previously unvisited arm of the maze (Fig. 21A), Cdkl5 
KO mice showed no preference toward the novel arm and entered randomly into 
the different arms approximately with the same frequency (Fig. 21A). This 
difference was not due to a reduced motility, as shown by the distance travelled 
by both mice (Fig. 21B), suggesting that Cdkl5 KO mice have deficits in spatial 
working memory. 
 
 
To sum up we demonstrated that Cdkl5 KO mice show hind-limb 
clasping, hypoactivity, deficits in spatial working memory and abnormal 
EEG responses to convulsants, features that may model the stereotypic hand 
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movements, hypotonia, cognitive disabilities and seizures, respectively, reported 
in the human condition. 
 
 
 
Figure 21 Working memory test in Cdkl5 knockout mice.  
 
(A) Cdkl5 KO female and male mice were tested in a single trial Y maze 
task, to measure arm alternation. The percentage of spontaneous 
alternations is defined as (total alternations/total arm entries-2) x 100. 
 
(B) Motor activity during testing is shown as the distance during the task.  
 
All data are presented as mean ± SEM. Statistical analysis: female, two-way 
ANOVA and Duncan’s test after ANOVA, *p < 0.05 ***p < 0.001; male, 
Student’s t test, **p<0.01. 
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4.5. Loss of Cdkl5 increases proliferation rate in the hippocampal 
dentate gyrus 
 
In order to establish whether lack of Cdkl5 affects cell proliferation in the 
hippocampal dentate gyrus (DG), wild-type and Cdkl5 KO mice aged 45 days 
(P45) were injected for 5 consecutive days with BrdU and sacrificed 24 hours 
after the last BrdU injection.  
 
Observation of images from wild-type (+/+) and homozygous (-/-) female 
Cdkl5 KO mice clearly show that mutant mice had more BrdU positive cells than 
wild-type littermates (Fig. 22A). A quantitative analysis revealed that the number 
of BrdU positive cells was significantly higher in both homozygous female (-/-) 
and hemizygous male (-/Y) Cdkl5 KO mice (+20% and +23%, respectively) 
compared to wild-type littermates (Fig. 22B). The number of BrdU positive cells 
in heterozygous female (+/-) Cdkl5 KO mice showed a slight but not significant 
increase in comparison with wild-type females (Fig. 22B), which may be 
consistent with a mosaic of knockout and wild-type cells as a result of X-
inactivation (Goto and Monk 1998). Similar results were obtained with 
immunohistochemistry for Ki-67, an endogenous marker of actively proliferating 
cells (Fig. 22C).  
 
The increased proliferative ability of neuronal precursor cells in 
Cdkl5 KO mice suggest that CDKL5 exerts a negative role on cell 
proliferation, similar to those observed in vitro. 
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Figure 22 Precursor proliferation in the dentate gyrus of Cdkl5 knockout 
mice. 
 
(A) Examples of sections processed for fluorescent immunostaining for BrdU 
from the DG of wild-type (+/+) and homozygous (-/-) female Cdkl5 KO 
mice. These animals were injected for 5 consecutive days with BrdU and 
sacrificed 24 hours after the last BrdU injection on P45. Calibrations = 200 
µm (lower magnification) and 80 µm (higher magnification). Abbreviations: 
DG, dentate gyrus; SGZ, subgranular zone; GR, granule cell layer; H, hilus. 
 
(B-C) Number of BrdU-positive cells (B) and Ki67-postivie cells (C) in the 
whole DG (GR+H) of homozygous (-/-), heterozygous (+/-) and wild-type 
(+/+) female Cdkl5 KO mice (upper histogram) and hemizygous (-/Y) and 
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wild-type (+/Y) male Cdkl5 KO mice (lower histogram). Abbreviations: DG, 
dentate gyrus; GR, granule cell layer; H, hilus. 
 
Values represent totals for one DG (mean ± SD). (*)p < 0.07; *p < 0.05; 
**p < 0.01 (Duncan’s test after ANOVA).  
 
 
 
 
4.6. Loss of Cdkl5 reduces the survival of newborn cells in the 
hippocampal dentate gyrus  
  
In order to evaluate the survival of the newborn cells, we counted the 
number of BrdU positive cells present in the hippocampal dentate gyrus (DG) 30 
days after BrdU administration, in mice aged 75 days (P75). Most of the surviving 
cells were located in the granule cell layer (GR), the final destination of new 
granule neurons. We found that both female (-/-) and male (-/Y) Cdkl5 KO mice 
had the same number of BrdU-labeled cells as wild-type littermates (Fig. 23A). 
This suggests that the surplus of cells born at P45 in the mutant mice was offset 
by a reduction in the survival rate. The ratio between the number of BrdU positive 
cells present in the DG at one month (Fig. 23A) and 24 hours (Fig. 22B) after the 
last BrdU injection provides an estimate of the net survival rate. We found that the 
surviving cells were 50% of the cells born at P45 in wild-type mice and 39±1.2 % 
and 43±1.9%, respectively, in female (-/-) (p< 0.01 two-tailed t-test) and male (-
/Y) Cdkl5 KO mice (p< 0.01 two-tailed t-test). A significant difference in the 
survival rate was also found in the heterozygous (+/-) female Cdkl5 KO mice 
compared to wild-type littermates (45±1.7 %; p<0.01 two-tailed t-test).  
 
In the attempt to examine whether lack of Cdkl5 triggers apoptotic cell 
death we evaluated the number of apoptotic cells in the DG by counting the 
number of cells that expressed cleaved caspase-3 (Fig. 23B). Most of the 
apoptotic cells were in the innermost portion of the GR. We observed an increase 
of cell death in both homozygous female (-/-) and hemizygous male (-/Y) Cdkl5 
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KO mice (+40% and +32%, respectively; Fig. 23B) vs. wild-type littermates and a 
less pronounced but significant increase also in heterozygous (+/-) females 
(+14%; Fig. 23B).  
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Figure 23 Survival of precursors in the dentate gyrus of Cdkl5 knockout 
mice. 
 
(A) Examples of sections processed for fluorescent immunostaining for BrdU 
from the DG of wild-type (+/+) and homozygous (-/-) female Cdkl5 KO 
mice. These animals were injected for five consecutive days with BrdU and 
sacrificed after one month after the last BrdU injection on P75. Calibrations 
= 50 µm.  
Number of BrdU-positive cells in the whole DG (GR+H) of homozygous (-/-
), heterozygous (+/-) and wild-type (+/+) female Cdkl5 KO mice (left 
histogram) and hemizygous (-/Y) and wild-type (+/Y) male mice (right 
histogram).  
(B) Examples of sections processed for fluorescent immunostaining for 
cleaved caspase-3 from the DG of wild type (+/+) and homozygous (-/-) 
female Cdkl5 KO mice. Calibrations = 40 µm.  
Number of cleaved caspase-3-positive cells in the whole DG (GR+H) of 
animals as in A. 
Values in (A-B) represent totals for one DG (mean ± SD). **p < 0.01; ***p 
< 0.001 (Duncan’s test after ANOVA). Abbreviations: DG, dentate gyrus; 
GR, granule cell layer; H, hilus. 
 
 
This evidence suggests that lack of Cdkl5 decreases the survival 
rate of newborn cells in Cdkl5 KO mice. 
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4.7. Loss of Cdkl5 specifically decreases survival of 
postmitotic neurons in the hippocampal dentate gyrus  
 
In order to examine the phenotype of the surviving cells 30 days after 
BrdU administration we performed an immunofluorescent double-labeling for 
BrdU and either a neuronal marker (NeuN) or an astrocytic marker (GFAP) on 
wild-type and Cdkl5 mutant mice. Both female (-/-) and male (-/Y) Cdkl5 KO 
mice had fewer (-20% and -30%, respectively) new neurons (NeuN/BrdU positive 
cells; Fig. 24A,B) in comparison with wild-type littermates, while the number of 
new astrocytes (GFAP/BrdU positive cells; Fig. 24A,B) was similar in both 
genotypes. Consequently a larger number of cells with an undetermined 
phenotype was present in female (-/-) and male (-/Y) Cdkl5 KO mice (+190% and 
+300%, respectively; neither; Fig. 24A,B). A similar effect was also found in 
heterozygous (+/-) female Cdkl5 KO mice compared to wild-type littermates (Fig. 
24A).  
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Figure 24 Phenotype of the surviving cells in the dentate gyrus of Cdkl5 
knockout mice. 
 
(A,B) Absolute number of surviving cells with neuronal phenotype 
(NeuN/BrdU), astrocytic phenotype (GFAP/BrdU) and undetermined 
phenotype (Neither/BrdU) in the DG (GR+H) of homozygous (-/-), 
heterozygous (+/-) and wild-type (+/+) female Cdkl5 KO mice (A) and 
hemizygous (-/Y) and wild-type (+/Y) male Cdkl5 KO mice (B). These 
animals were injected for five consecutive days with BrdU and sacrificed 
after one month after the last BrdU injection on P75.  
 
Values represent totals for one DG (mean ± SD). **p < 0.01; ***p < 0.001 
(Duncan’s test after ANOVA). 
 
 
 
These data show that the lack of Cdkl5 dampens the formation of new 
granule neuron without affecting astrogliogenesis.  
 
 
The hippocampal dentate gyrus (DG) is formed over a long time period 
that begins during gestation and continues in the postnatal period. It contains a 
neurogenic niche, the subgranular zone (SGZ), which is inhabited by a 
heterogonous population of cells and cellular elements, which play an important 
role in neurogenesis. In the course of adult hippocampal neurogenesis, new cells 
within the SGZ of the DG go through a series of stages associated with 
proliferative activity, from stem cell (type 1) over intermediate progenitor stages 
(type 2/3) to postmitotic maturation (Fig. 25A). Doublecortin (DCX), a 
microtubule associated protein, is widely expressed by the actively dividing type 
2b and type 3 progenitor cells and also by immature granule neurons (Fig. 25A). 
As shown in Fig. 25A,B, these cell types can be distinguished based on their 
morphology: while type 2b/3 cells are orientated parallel to the SGZ (Fig. 25A,B; 
asterisk), immature granule neurons have a vertical orientation and extend long 
apical processes into the granule cell layer (GR) (Fig. 25A,B; arrows). Based on 
these features, we determined whether loss of Cdkl5 specifically affects a 
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particular stage of granule cell formation. We found that Cdkl5 KO mice had 
more 2b/3 type cells in comparison with wild-type littermates but a reduced 
number of immature neurons (Fig. 25C). These data indicate that the lack of 
Cdkl5 affects in an opposite manner type 2b/3 cells (mitotic cells) and 
differentiating (postmitotic) neurons. This is consistent with the increased number 
of undifferentiated cells (neither) and the reduced number of cells differentiated 
into neurons (BrdU/NeuN positive cells) found in Cdkl5 KO mice (see Fig. 
24A,B).  
 
In order to establish whether the reduced number of immature neurons 
in Cdkl5 KO mice was due to an increase in cell death we evaluated the number 
of cells that were positive for both DCX and cleaved caspase-3. We found that 
hemizygous male (-/Y) Cdkl5 KO mice showed a notably higher number of DCX/ 
cleaved caspase-3 positive immature neurons in comparison to wild-type 
littermates (+/Y) (Fig. 25D,E), with no difference in the number of DCX/caspase-
3 positive 2b/3 type cells (Fig. 25D,E). Similar results were obtained also in the 
female Cdkl5 KO mice (data not shown). 
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Figure 25 Survival of post-mitotic neurons in the dentate gyrus of Cdkl5 
knockout mice. 
 
(A) Schematic representation of adult hippocamapal neurogenesis. The 
subgranular zone (SGZ) of the dentate gyrus (DG) is inhabited by a 
heterogonous population of cells which go through a series of stages 
associated with proliferative activity: from stem cell (type 1 cells, expressing 
Nestin and SOX2) over intermediate progenitor stages (type 2a/b and type 3) 
to postmitotic maturation. Doublecortin (DCX), a microtubule associated 
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protein, is widely expressed by the actively dividing type 2b and type 3 
intermediate progenitor cells and also by immature granule neurons and 
these two cell types can be distinguished based on their morphology: while 
type 2b/3 cells are orientated parallel to the SGZ (red asterisks), immature 
granule neurons have a vertical orientation and extend long apical 
processes into the granule cell layer (GR). 
 
(B) Examples of sections processed for DCX immunostaining from the DG of 
wild-type (+/Y) and hemizygous male (-/Y) Cdkl5 KO mice. The high 
magnification photomicrograph show immature DCX-positive neurons 
(vertical orientation with apical processes; black arrows) in the innermost 
portion of the GR and type 2b/3 DCX-positive granule cells (orientated 
parallel to the GR; red asterisks) in the SGZ. Calibrations = 60 µm (lower 
magnification) and 15 µm (higher magnification). 
 
(C) Number of DCX-positive cells in the whole DG (GR+H), divided in 
immature neurons and type 2b/3 cells, of homozygous (-/-), heterozygous (-
/+) and wild-type (+/+) female Cdkl5 KO mice (left histogram) and 
hemizygous (-/Y) and wild-type (+/Y) male Cdkl5 KO mice (right histogram).  
 
(D) Examples of ultra-thin sections processed for immunostaining for 
cleaved caspase-3 and DCX from the DG of wild-type male (+/Y) mice. 
Computer-based image overlay of two serial ultra-thin sections allow to 
identify DCX-positive cells (black asterisks)/cleaved caspase-3-positive cells 
(red arrow). Calibrations = 15 µm. 
 
(E) Number of cleaved caspase-3/DCX-positive cells in the whole DG 
(GR+H), divided in immature neurons and type 2b/3 cells, of hemizygous (-
/Y) and wild-type (+/Y) male Cdkl5 KO mice. Data are expressed as fold 
difference in comparison to wild-type mice.  
 
Values in (B-E) represent totals for one DG (mean ± SD). *p < 0.05; **p < 
0.01 (Duncan’s test after ANOVA).  
 
 
 
 
This evidence suggests that the reduced number of new neurons in 
Cdkl5 KO mice (see Fig. 24A and Fig. 25C) is due to an increase in cell death 
that specifically affects early postmitotic neurons.  
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4.8. Loss of Cdkl5 results in reduced net number of granule cells 
in the dentate gyrus 
 
To establish the impact of the reduction in the number of newly formed 
granule neurons in Cdkl5 KO mice on overall granule cell number, we 
stereologically evaluated total granule cell number in mice aged 45 (Fig. 26) and 
75 days (data not shown). We found no difference between Cdkl5 KO and wild-
type mice in the volume of the granule cell layer (data not shown), but a reduced 
granule cell density (Fig. 26B) and reduced number of granule cells (Fig. 26C) in 
Cdkl5 KO mice compared to wild-type littermates. The reduction in cell number 
was -12% ,–8% and -10%, respectively, in homozygous female (-/-), heterozygous 
female (+/-) and hemizyogous male (-/Y) Cdkl5 KO mice compared to their wild-
type littermates (Fig. 26C).  
Consistent with the higher apoptotic cell death in Cdkl5 KO mice 
estimated by cleaved caspase-3 immunostaining (Fig. 23B), we noted a higher 
number of pyknotic nuclei in the innermost granule cell layer in the Cdkl5 mutant 
mice, indicating a larger number of dying cells (Fig. 26A, yellow arrowheads). 
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Figure 26 Net number of granule cells in the dentate gyrus of Cdkl5 
knockout mice. 
 
(A) Examples of sections processed for Hoechst immunostaining from the 
DG of wild-type (+/+) and homozygous (-/-) female Cdkl5 KO mice.  
 
(B-C) Density of granule cells (B) and total number of granule cells (C) in 
P45 homozygous (-/-), heterozygous (+/-) and wild-type (+/+) female Cdkl5 
KO mice (left histogram) and hemizygous (-/Y) and wild-type (+/Y) male 
Cdkl5 KO mice (right histogram).  
 
Values refer to one DG (mean ± SD). **p < 0.01; ***p < 0.001 (Duncan’s 
test after ANOVA). 
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4.9. Loss of Cdkl5 results in reduced dendrite tree and synaptic 
contacts of newborn granule cells  
 
To establish the effect of loss of Cdkl5 on dendritic development of 
newborn granule cells, we examined the dendritic morphology of DCX-positive 
cells. Dendritic morphology of newborn granule cells can be analyzed with 
immunohistochemistry for DCX, taking advantage of the expression of this 
protein in the cytoplasm of immature neurons during the period of neurite 
elongation (from one to four weeks after neuron birth). Fig. 25B clearly shows 
that in Cdkl5 KO mice DCX-positive immature neurons had fewer processes than 
in their wild-type counterparts. Quantification of the dendritic size of DCX-
positive cells showed that homozygous female (-/-) and hemizygous male (-/Y) 
Cdkl5 mutant mice had a shorter dendritic length (-44% and -34% respectively; 
Fig. 27A) and a reduced number of segments (-46% and -36% respectively; Fig. 
27B) than wild-type littermates. The decrease in the dendritic length and in the 
number of segments in heterozygous (+/-) female Cdkl5 KO mice (-41% and -
45% respectively; Fig. 27A,B) was very similar to that found in homozygous 
female (-/-) mutant mice . 
 
 
To dissect the effects of loss of Cdkl5 on details of the dendritic 
architecture we examined each dendritic order separately. A striking difference 
between wild-type and Cdkl5 KO mice was the absence of branches of higher 
order in the mutant mice. While wild-type (+/+) female mice had up to 9 orders of 
branches, homozygous (-/-) and heterozygous (+/-) female Cdkl5 KO mice 
completely lacked branches of orders 7 and 8-9 (Fig. 27C, arrows). Analysis of 
the branch length of individual orders showed reduced branch length of orders 4-6 
in female Cdkl5 KO mice (Fig. 27C). In contrast, analyzing the length of the 
branches of orders 1-3 we found no difference between wild-type and mutant 
mice (Fig. 27C). Similar results were also obtained in hemizygous male (-/Y) 
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Cdkl5 mutant mice compared to wild-type littermates (absence of branches of 
higher order 8-10 and reduced branch length of order 7 (Fig. 27C). Analysis of the 
number of branches showed that homozygous (-/-) and heterozygous (+/-) female 
Cdkl5 KO mice had a similar number of branches of order 1 -4 as wild-type mice, 
fewer branches of orders 5-6 and, as noted above, no branches of higher orders. In 
the male mutant mice (-/Y), there was a progressive worsening in branch number 
from order 5 and no branches of orders 8-10 (Fig. 27D). 
 
 
 Taken together these data indicate that in Cdkl5 KO mice the 
dendritic tree of the newborn granule cells is hypotrophic and that this effect 
is mainly due to a reduction in the number of branches of intermediate order 
and a lack of branches of higher order.  
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Figure 27 Dendritic architecture of newborn granule cells of Cdkl5 
knockout mice. 
 
(A,B) Mean total dendritic length (A) and mean number of dendritic 
segments (B) in homozygous (-/-), heterozygous (-/+) and wild-type (+/+) 
female Cdkl5 KO mice (left histogram) and hemizygous (-/Y) and wild-type 
(+/Y) male Cdkl5 KO mice (right histogram). 
 
(C,D) Quantification of the mean length (C) and mean number (D) of 
branches of the different orders in animals as in A. The arrows indicate the 
absence of branches in Cdkl5 KO mice.  
 
Values represent as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001 
(Duncan’s test after ANOVA). 
116 
 
It is likely that a reduction in connectivity is the counterpart of the 
severe dendritic hypotrophy that characterizes the newborn granule cells of 
Cdkl5 KO mice. Synaptophysin (SYN; also known as p38) is a synaptic 
vesicle glycoprotein, that is a specific marker of presynaptic terminals. 
Quantitative analysis showed that in Cdkl5 KO mice the optical density of 
SYN was significantly lower than in wild-type littermates in the outer (O), 
middle (M) and inner (I) molecular layer (Fig. 28A,B), suggesting that 
Cdkl5 mutant mice had fewer synaptic contacts in the dentate gyrus. 
 
 
 
 
 
 
Figure 28 Synaptic contacts in the dentate gyrus of Cdkl5 knockout mice. 
 
(A) Images of sections processed for synaptophysin immunofluorescence 
from the DG of wild-type (+/+) and homozygous (-/-) female Cdkl5 KO 
mice. Calibration: 50 µm.  
(B) Optical density of synaptophysin immunoreactivity in the inner (I), 
middle (M) and outer (O) third of the molecular layer of homozygous (-/-), 
heterozygous (+/-) and wild-type (+/+) female Cdkl5 KO mice (left 
histogram) and hemizygous (-/Y) male Cdkl5 KO mice and wild-type (+/Y) 
littermates (right histogram). 
 
Data are given as fold difference vs. inner molecular layer of wild-type mice.  
Values represent as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001 
(Duncan’s test after ANOVA). 
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4.10. Loss of Cdkl5 increases proliferation rate and decreases 
survival of precursor cells in the subventricular zone 
 
Neurogenesis persists in the postnatal and adult brain in two distinct brain 
regions, the subventricular zone (SVZ) and the hippocampal dentate gyrus (DG).  
 
In order to establish if the increased proliferation of precursor cells shown 
in the DG of Cdkl5 KO mice (see Fig. 22) was also present in the SVZ we 
evaluated proliferation in this area by Ki-67 immunohistochemistry on P45 mice. 
SVZ proliferating precursor cells are located in the lateral wall of the ventricle, at 
the corner formed by the lateral wall and the dorsal roof of the ventricle and at the 
lower corner of the ventricle (Fig. 29A). Qualitative observation of images from 
Cdkl5 KO and wild-type mice clearly showed that Cdkl5 mutant mice had more 
Ki-67 positive cells (Fig. 29A) compared to wild-type littermates. Quantification 
of the number of Ki-67 positive cells in the SVZ showed that homozygous female 
(-/-) and hemizygous male (+/Y) Cdkl5 KO mice had more Ki-67 positive cells 
(+30% and +20%, respectively; Fig. 29A) vs. wild-type littermates. A less 
pronounced but significant disparity in the proliferation rate was also found in 
heterozygous female (+/-) Cdkl5 KO mice (+14%; Fig. 29A).  
 
In order to establish whether the greater proliferation in the SVZ of Cdkl5 
KO mice was accompanied by a higher apoptotic cell death, similar to those 
observed in the DG (see Fig. 23B). we performed immunohistochemistry for 
cleaved caspase-3 also in this area. We found that Cdkl5 KO mice had more 
apoptotic cells in this area compared to wild-type littermates (Fig. 29B), similar as 
those observed in the DG. More caspase-3 positive cells were present in the SVZ 
of both homozygous female (-/-) and hemizygous male (+/Y) Cdkl5 KO mice 
(+21%; Fig. 29B) and in heterozygous female (+/-) Cdkl5 KO mice (+15%; Fig. 
29B).  
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Figure 29 Precursor proliferation and survival in the subventricular zone 
of Cdkl5 knockout mice. 
 
(A) Examples of sections processed for fluorescent immunostaining for Ki-67 
from the SVZ of wild-type (+/+) and homozygous female (-/-) Cdkl5 KO 
mice aged P45. Calibrations = 200 µm.  
Number of Ki-67 positive cells in the SVZ of homozygous (-/-), heterozygous 
(+/-) and wild-type (+/+) female Cdkl5 KO mice (left histogram) and 
hemizygous (-/Y) and wild-type (+/Y) male Cdkl5 KO mice (right histogram).  
(B) Examples of sections processed for fluorescent immunostaining for 
cleaved caspase-3 from the SVZ of wild-type (+/+) and homozygous female 
(-/-) Cdkl5 KO mice aged P45. Calibrations = 200 µm.  
Number of cleaved caspase-3 positive cells in the SVZ of animals as in A.  
Values represent totals for one hemisphere (mean ± SD). *p < 0.05; **p < 
0.01 (Duncan’s test after ANOVA). Abbreviations: d, dorsal; l, lateral; LV, 
lateral ventricle; m, medial; SVZ, subventricular zone. 
 
 
Taken together, our findings of increased proliferation and cell death in 
the DG and SVZ of Cdkl5 KO mice suggest that these developmental 
alterations are generalized defects of neuronal precursor cells in Cdkl5 KO 
mice. 
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4.11. Alterations in Akt/GSK3-β pathway underlie developmental 
defects in Cdkl5 knockout mice 
 
Glycogen synthase kinase-3 (GSK3-β) is a ubiquitously active 
serine/threonine kinase which is inhibited upon phosphorylation at Ser9 by 
activated protein kinase B (PKB/Akt). Dephosphorylated GSK3-β is a crucial 
inhibitory regulator of many neuronal functions, including neurite outgrowth, 
synapse formation, neurogenesis and survival of newly generated neurons (Cole 
2012). The Akt/GSK3-β pathway exerts its functions by modulating the activity of 
a wide range of substrates (Cole 2012). An outline of key elements of this 
pathway is reported in Fig. 30.  
 
 
 
Figure 30 Diagram of Akt/GSK3-β signaling cascade.  
 
The proteins emphasized in red showed significantly altered phosphorylation 
or expression whereas proteins emphasized in blue did not show 
significantly alteration in Cdkl5 KO mice in comparison to wild-type 
littermates. Lithium, an inhibitor of GSK3-β, is green colored. 
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In the current study we were interested to establish whether the 
Akt/GSK3-β pathway is deregulated in Cdkl5 KO mice. In order to address this 
issue we performed western blot analysis on hippocampal extracts from Cdkl5 
KO and wild-type mice aged P19. We found a deregulation in several substrates 
of this pathway (Fig 30A, 31A,B).  
 
Evaluation of the phosphorylation levels of the Akt/GSK3-β pathway 
showed lower phosphorylation levels of: i) PDK1 (PDK1 stands at the head of the 
Akt/GSK-3 β pathway by phosphorylating Akt), ii) Akt, at its two critical residues 
namely Thr308 and Ser473, iii) GSK3-β at Ser9 (its inhibitory site) and iv) CREB 
at Ser133 in Cdkl5 KO mice compared to wild-type littermates (Fig. 31A,B). 
While CREB phosphorylation and consequent DNA binding is inhibited by 
activated (dephosphorylated) GSK3-β (Grimes and Jope 2001), CRMP2 
phosphorylation and activity are positively modulated by GSK3β (Yoshimura et 
al. 2005). In contrast, GSK3-β controls the amount of β-catenin by negatively 
regulating β-catenin protein stability (Wada 2009). In line with an increased 
activity of GSK3-β, we found higher phosphorylation levels of CRMP2 at Thr514 
and lower levels of β-catenin (Fig. 31A,B) in Cdkl5 KO mice. No differences 
were found the phosphorylation levels of ERK (Fig. 31A,B), suggesting a specific 
alteration of the Akt/GSK3-β pathway in the absence of Cdkl5. 
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Figure 31 Akt/GSK3- β pathway immunoreactivity in the hippocampus of 
Cdkl5 knockout mice. 
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(A) Examples of western blots of hippocampal protein extracts of P-PDK1, 
P-Akt (Ser437, Thr308), P-ERK, P-GSK3-β (Ser9), P-CREB (Ser133), P-
CRMP2 (Thr514) and β -catenin levels in the hippocampal formation of 
homozygous (-/-), heterozygous (+/-) and wild-type (+/+) female Cdkl5 KO 
mice and hemizygous (-/Y) and wild-type (Y/+) male Cdkl5 KO mice.  
(B) Histograms show phosphorylated protein levels of P-PDK1, P-Akt 
(Ser437, Thr308), P-ERK, P-GSK3- β (Ser9), P-CREB (Ser133), P-CRMP2 
(Thr514) normalized to respective total protein levels and β -catenin levels 
normalized to GADPH of Cdkl5 KO mice. Data are given as fold difference 
vs. wild-type mice.  
Values represent mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001 
(Duncan’s test after ANOVA).  
 
 
This evidence suggests that alteration of the Akt/GSK3-β pathway may 
underlie the developmental defects due to loss of Cdkl5.  
 
To clear this issue, we exploited cultures of neuronal precursor cells (NPCs) 
from Cdkl5 KO mice. We first sought to establish whether cultures of NPCs 
exhibit the same defects observed in vivo. Neurospheres derived from the SVZ of 
homozygous (-/-) Cdkl5 KO females exhibited a higher proliferation rate vs. the 
wild-type counterparts (+15%; Fig. 32A). No difference in apoptotic cell death 
was observed between wild-type and Cdkl5 knockout neurospheres, as estimated 
by cleaved caspase-3 immunostaining (Fig. 32A) and pyknotic appearance of the 
nuclei of dying cells (data not shown). This confirms that loss of Cdkl5 does not 
induce an increase in cell death during the stage of proliferation of NPCs.  
 
To determine the effect of loss of Cdkl5 on cell death in post-mitotic NPCs, 
we evaluated the number of cleaved caspase-3 positive cells after 1 day in 
differentiating culture conditions. We found that differentiating NPCs from Cdkl5 
KO mice had a notably higher number of caspase-3 positive cells (Fig. 32B), 
confirming that loss of Cdkl5 is accompanied by an increase in cell death during 
the stage of differentiation. 
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Evaluation of the number of new neurons (β-tubulin III-positive cells) and 
new astrocytes (GFAP-positive cells) after 7 days of differentiation, showed that 
in differentiated Cdkl5 knockout NPCs the number of neurons was remarkably 
smaller compared to wild-type NPCs (-82% Fig. 32C), while there was no 
difference in the number of astrocytes (Fig. 32C). This confirms that loss of Cdkl5 
specifically decreases the survival of postmitotic neurons. Assessment of neurite 
outgrowth in β-tubulin III-positive cells revealed that neurons generated from 
Cdkl5 knockout NPCs were less differentiated compared to wild-type neurons (-
40%; Fig. 32C). These results confirm that post-mitotic NPCs from Cdkl5 KO 
mice have an intrinsic defect, not only in cell survival, but also in neuronal 
maturation.  
 
Evaluation of the Akt/GSK3-β pathway activation in cultures of Cdkl5 KO 
NPCs showed lower levels of phosphorylated Akt and GSK3-β (Fig. 32D).  
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Figure 32 NPCs from Cdkl5 knockout mice show similar defects as those 
observed in vivo.  
 
(A) Cell proliferation and apoptotic cell death in proliferating neurospheres 
from wild-type and Cdkl5 KO mice. Images of BrdU-positive cells (red) in 
neurospheres from female wild-type (+/+) and homozygous (-/-) Cdkl5 KO 
mice. Cell nuclei were stained using Hoechst dye (blue). Scale bar: 40µm.  
Percentage of BrdU-positive cells (left histogram) and cleaved caspase-3-
positive cells (right histogram) in neurospheres from female wild-type (+/+) 
and homozygous (-/-) Cdkl5 KO mice.  
(B) Apoptotic cell death in differentiating NPCs from wild-type and and 
Cdkl5 KO mice. Images of cleaved-caspse-3-positive cells (red) of NPCs 
from female wild-type (+/+) and homozygous (-/-) Cdkl5 KO mice after 1 
day of differentiation. Cell nuclei were stained using Hoechst dye (blue). 
Scale bar: 20 µm.  
126 
 
Percentage of cleaved caspase-3-positive cells in differentiate NPCs from 
female wild-type (+/+) and homozygous (-/-) Cdkl5 KO mice.  
(C) Phenotype and neuronal morphology of differentiated NPCs from wild-
type and Cdkl5 KO mice. Representative double-fluorescence images of 
NPCs from female wild-type (+/+) and homozygous (-/-) Cdkl5 KO mice 
after 6 days of differentiation. Cells with neuronal phenotype are 
immunopositive for β-tubulin III (red) and cells with astrocytic phenotype 
are immunopositive for GFAP (green). Cell nuclei were stained using 
Hoechst dye (blue).  
Stacked column charts represent the percentages of β-tubulin III-positive 
cells, GFAP-positive cells and cells with undetermined phenotype (Neither) 
of the total cell population after 6 days of in vitro differentiation.  
Quantification of neurite outgrowth of differentiated neurons in female wild-
type (+/+) and homozygous (-/-) Cdkl5 KO mice. 
(D) Western blot quantification of P-Akt (Ser437) and P-GSK3-β (Ser9) 
expression, normalized to respective total protein levels in differentiated 
NPCs from wild-type and Cdkl5 KO mice. Data are given as fold difference 
vs. wild-type mice.  
 
Values in (A-D) represent in mean ± SD. *p < 0.05; **p < 0.01; ***p < 
0.001 (two-tailed t-test). 
 
 
 
In order to obtain evidence that the neurodevelopmental defects observed 
in Cdkl5 KO mice and Cdkl5 knockout NPCs were due to loss of Cdkl5, we re-
expressed Cdkl5 in cultures of NPCs. We found that adenvirus-mediated 
expression of Cdkl5 in NPCs from Cdkl5 KO mice (Fig. 33B) restored cell 
proliferation (Fig. 33A), neuronal survival and maturation (Fig. 33C,D). 
Importantly, we also found a parallel restoration of the phosphorylation levels of 
Akt and GSK3-β (Fig. 33E), confirming the hypothesized link between CDKL5 
and the Akt/GSK3-β pathway.  
 
We next treated Cdkl5 knockout NPCs with lithium, a well-known 
inhibitor of GSK3-β activity (Fig. 30). We found that, in NPCs from Cdkl5 KO 
mice, the lithium-induced increase in the GSK3-β phosphorylation (Fig. 33E) was 
accompanied by complete restoration of neuronal survival, number of new 
neurons and neuronal maturation (Fig. 33C,D).  
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Figure 33 Akt/GSK3- β pathway immunoreactivity in NPCs from Cdkl5 
knockout mice.  
 
(A) Percentage of BrdU-positive cells (left histogram) and cleaved caspase-3 
positive cells (right histogram) from untreated female wild-type (+/+) and 
homozygous (-/-) Cdkl5 KO mice and in neurospheres from homozygous (-/-) 
Cdkl5 KO mice infected with CDKL5 adenovirus particles (MOI: 100) for 72 
h starting from DIV1.  
(B) Representative example of a western blot showing Cdkl5 expression in 
neurospheres as in (A). 
(C) Percentage of cleaved caspase-3 positive cells from differentiating NPCs 
from female wild-type (+/+) and homozygous (-/-) Cdkl5 KO mice. Cdkl5 
knockout NPCs (-/-) were infected with CDKL5 adenovirus particles (MOI: 
100) or treated with Lithium (4 mM) throughout the entire differentiation 
period. 
(D) Representative double-fluorescence images of NPCs as in (C) after 6 
days of differentiation. Cells with neuronal phenotype are immunopositive 
for β-tubulin III (red) and cells with astrocytic phenotype are 
immunopositive for GFAP (green). Cell nuclei were stained using Hoechst 
dye (blue). NPC cultures were treated as in (C). 
Stacked column charts represent the percentages of β-tubulin III-positive 
cells, GFAP-positive cells and cells with undetermined phenotype (Neither) 
of the total cell population after 6 days of in vitro differentiation.  
Quantification of neurite outgrowth of differentiated neurons in female wild-
type (+/+) and homozygous (-/-) Cdkl5 KO mice treated as in (C). 
(E) Western blot quantification of P-Akt (Ser437) and P-GSK3-β (Ser9) 
expression normalized to respective total protein levels in differentiated 
NPCs from wild-type and Cdkl5 KO mice treated as in (C). Data are given 
as fold difference vs. wild-type mice.  
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Values represent mean ± SE. *p < 0.05; **p < 0.01; ***p<0.001 as 
compared to the wild-type condition; #P<0.05, ##P<0.01 as compared to 
untreated Cdkl5 KO samples (Duncan’s test after ANOVA). 
 
 
 
 
 
These data suggest that alteration of the Akt/GSK3-β signaling, due to loss of 
CDKL5 expression, may be responsible for the developmental alterations 
observed in Cdkl5 KO mice. 
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5. DISCUSSION 
 
In the last few years CDKL5 has been associated with early-onset epileptic 
encephalopathies characterized by the manifestation of intractable epileptic 
seizures within the first weeks of life, severe developmental delay and RTT-like 
features. The association of CDKL5 and neurodevelopmental disorders and its 
high expression levels in the maturing brain (Rusconi et al. 2008; Chen et al. 
2010) underscore the important of this kinase for proper brain development. In 
spite of the clear importance of CDKL5 for the central nervous system, the 
biological functions of this kinase were largely unknown.  
 
Here we show for the first time that CDKL5 affects both proliferation and 
differentiation of neural cells. In particular in this study, using of a newly created 
Cdkl5 KO mouse model, we report the role of Cdkl5 during postnatal 
neurogenesis. Precursor cell proliferation and survival are two forces that control 
the generation of the correct neuron number. Lack of Cdkl5 leads to increased 
proliferation of neuronal precursor cells. The final neuronal output, however, was 
reduced due to the greater apoptosis of post-mitotic cells. Moreover, lack of Cdkl5 
led to decreased neuronal maturation.  
 
 
Our hypothesis from these results is that CDKL5 is a critical factor 
controlling the balance between progenitor self-renewal, survival and maturation 
during postnatal neurogenesis. 
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5.1. CDKL5 induces differentiation and inhibits proliferation of 
the SH-SY5Y neuroblastoma cell line 
 
 
To establish the role of CDKL5 on neuronal maturation, we used human 
neuroblastoma cell lines as a neuronal model system. We first provide evidence 
that in the SH-SY5Y neuroblastoma cell line there is a direct correlation between 
neurite elongation and CDKL5 expression. This evidence is consistent with recent 
studies showing that Cdkl5 regulates neurite growth and dendritic arborization of 
cortical rat neurons (Chen et al. 2010) and strengthen the role of CDKL5 during 
development as a pro-differentiating gene. 
Neuronal differentiation and proliferation are two closely linked processes 
during brain development. Neuronal differentiation requires the progenitor cells to 
exit the cell cycle and the processes of proliferation and differentiation intersect at 
the regulation of cell cycle regulatory proteins. Proliferation promotes positive 
regulation of cell cycle proteins (e.g. cyclins and cyclin-dependent kinases (Cdk)), 
whereas differentiation results in inhibition of these cell cycle proteins (Ohnuma 
et al. 2001). We found that in the SH-SY5Y cell line induction of CDKL5 
expression caused a strong inhibition of cell proliferation with no increase in 
apoptotic cell death. Inhibition of cell proliferation was due to a block of cell 
cycle progression in the G0/1 phase, supporting the view that CDKL5 can function 
as an anti-proliferative gene.  
 
Our findings show that CDKL5 affects both neurite growth and cell 
proliferation, suggesting that CDKL5 may not only modulate dendritic 
maturation, as shown by Chen et al. (Chen et al. 2010), but also cell proliferation 
in the developing brain and underline the important role of CDKL5 during correct 
brain development. The fact that CDKL5 plays a role in the control both of 
neuronal proliferation and differentiation is consistent with the appearance of 
neurological symptoms during the early period of brain maturation in patients 
with mutations of CDKL5. 
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5.2. Cdkl5 knockout mice recapitulate several core features of the 
CDKL5 disorder  
 
Behavioral characterizations of constitutive Cdkl5 KO mice show that 
they recapitulate several features that mimic the clinical features described in 
CDKL5 patients and are a useful tool to investigate phenotypic and functional 
aspects of Cdkl5 loss. In particular Cdkl5 KO mice showed hind-limb clasping 
and hypoactivity, features that may model the stereotypic hand movements and 
hypotonia, respectively, reported in the human condition.  
 
Although early-onset seizures are a key feature of CDKL5 disorder, we 
failed to detect any spontaneous seizure or epileptiform EEG activity under 
baseline conditions in Cdkl5 mutant mice. Moreover, following pharmacological 
induction of seizures with kainic acid no evidence emerged for increased 
susceptibility for seizures or epileptiform activity in Cdkl5 KO mice, although we 
found an increased duration and reduced frequency of epileptiform events as well 
as reduced EEG power in response to the high dose of kainic acid. These results 
are in line with those observed by Wang and colleagues in a different Cdkl5 KO 
mouse model recently created (Wang et al. 2012). Wang et al. describe several 
behavioral abnormalities including autistic-like behavior deficits, such as 
impaired motor control and decreased anxiety in their Cdkl5 KO mouse model, 
but also in this mouse model spontaneous seizure or epileptiform activity are 
absent (Wang et al. 2012). At the moment it remains unclear whether the lack of 
spontaneous seizures observed in both Cdkl5 KO mice is the result of differences 
in the function of the mouse and human protein, in its interactors, or the presence 
of genetic modifiers. 
 
We found that loss of Cdkl5 results in impaired hippocampus-
dependent learning and memory, consistently with the cognitive deficits that 
characterize CDKL5 patients. Memory loss and subsequent cognitive impairment 
might occur through diminished neurogenic capacity within the principal brain 
133 
 
areas involved in memory and learning, such as the hippocampus. Results from 
several laboratories suggest that postnatal hippocampal neurogenesis is functional 
and participates in learning and memory consolidation (van Praag et al. 2002). In 
mammals, increased neurogenesis is mediated by environmental factors such as 
exercise (van Praag et al. 2005) or stimuli-enriched environments (Tashiro et al. 
2007) that concomitantly improve learning and memory capacities. In the adult 
human hippocampus, both structural and functional changes have been 
demonstrated in individuals exposed to intensive spatial learning (Maguire et al. 
1997). Inhibition of neurogenesis is known to impair learning and memory (Shors 
et al. 2001) and increased neurogenesis improves LTP of synaptic transmission 
(van Praag et al. 1999).  
 
Our finding that loss of Cdkl5 impaired hippocampal neurogenesis could 
underlie hippocampal-dependent memory performance alterations that 
characterized Cdkl5 mutant mice.  
 
 
5.3. Cdkl5 has an important role in postnatal development of the 
hippocampal dentate gyrus 
 
In rodents, the hippocampal dentate gyrus produces its neurons mainly 
postnatally (Altman and Bayer 1990) and this makes the hippocampus an ideal 
structure in order to examine the role of CDKL5 on fundamental 
neurodevelopmental processes such as neurogenesis and dendritic development. 
Adult hippocampal neurogenesis is a constitutive but highly regulated process that 
occurs in a neurogenic niche, the subgranular zone (SGZ) of the dentate gyrus 
(DG). Type 1 neural stem cells (NSCs), characterized by nestin and Sox2/BLBP 
expression, exhibit morphology typical of radial glia and divide asymmetrically to 
self-renew and give rise to daughter cells, termed intermediate progenitor cells 
(IPCs), a type of transit amplifying cell (Kempermann et al. 2004). 
Undifferentiated IPCs (type 2a and type 2b) divide rapidly to produce neuronal 
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committed IPCs (type 3) and are responsive to stimuli that affect neuron 
production in the DG (Encinas et al. 2006). Type 3 IPCs generate immature 
neurons that within 1 month during which network connections are established 
and the selection for long-term survival occurs, integrate into the granule layer 
(GR) as mature granule cells (Kempermann et al. 2004) (see Fig.14 introduction, 
see Fig 25A results). The majority of these immature neurons are subject to a 
selection process, during which they are either recruited into function or 
eliminated (Biebl et al. 2000). 
 
We demonstrated here that Cdkl5 knockdown leads to an increase in 
proliferation of IPCs of the DG. This result is in line with the anti-proliferative 
role observed also in human neuroblastoma cell line and support the view that 
CDKL5 can function as an inhibitor of progenitor cell proliferation.  
 
Interestingly we report an increased number of dead cells in the Cdkl5 
deleted DG. Using double-labeling with apoptotic marker and immature neuronal 
marker we found that Cdkl5 expression specifically influence immature granule 
cells survival. These findings suggest that CDKL5 may be required for 
postmitotic neuron survival, and may elucidate the role of the higher expression of 
CDKL5 in postmitotic/differentiating neurons seen in vitro.  
 
Based on these results, we assume that CDKL5 might influence exit of 
the cell cycle of IPCs and survival of post-mitotic neurons by prompting 
immature neurons to differentiate and recruiting into function neurons. 
Consistently with increased cell death of post-mitotic granular neurons, Cdkl5 KO 
mice were characterized by hypocellularity in the dentate gyrus. 
  
Phenotypic analysis of the BrdU-labeled cell population in the dentate 
gyrus at 4 weeks after labeling revealed that loss Cdkl5 did not affect 
astogliogenesis. It is reasonable to suppose that loss of Cdkl5 suppresses 
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neuronal but not glial survival/differentiation. This is in agreement with the 
predominant expression of CDKL5 in neurons (Rusconi et al. 2008). 
 
Dendritic arborization is significantly reduced in cortical pyramidal 
neurons from both RTT patients (Armstrong et al. 1999; Belichenko et al. 2008; 
Belichenko et al. 2009) as well as Mecp2 KO mice (Kishi and Macklis 2005; 
Stuss et al. 2012). Actually it is not known if similar deficits exist also in the 
brains of subjects carrying CDKL5 mutations. In order to establish the effect of 
loss of Cdkl5 on dendritic development of newborn granule cells, we examined 
the dendritic morphology of immunohistochemistry for DCX and found that 
Cdkl5 KO mice show a significant reduces in dendritic length. Our detailed 
analysis of the dendritic arborization of new generated granule neurons of Cdkl5 
KO mice clearly shows that dendritic complexity was significantly reduced, 
mainly due to absence of dendritic arbors of higher order. Dendritic pathology is 
also a possible substrate for cognitive disability in different conditions. In RTT, 
the pathogenesis of dendritic abnormalities is distinctive and appears to correlate 
with the cognitive profile. Likewise individuals with CDKL5 disorder show 
impairment in long-term memory, a function that requires the participation of the 
hippocampal region. It would be reasonable to hypothesize that the 
hypocellularity and the dendritic hypotrophy observed in hippocampal 
dentate gyrus of the Cdkl5 KO mice could lead to memory loss and thereby 
to cognitive impairment, in CDKL5-related disease patients.  
 
Most CDKL5 patients are females who are heterozygous for CDKL5 
deficiency due to random X-chromosome inactivation (XCI). Mammalian female 
cells randomly inactivate one of the two X chromosomes in somatic cells, and the 
genes on the inactive X chromosome (with a few exceptions) are not expressed. 
XCI occurs before the completion of gastrulation during early embryonic 
development and is believed to be irreversible (Plath et al. 2002). Skewed XCI 
can occur when there is preferential inactivation of the maternal or paternal X 
chromosome and has been linked to both autism (Talebizadeh et al. 2005) and X-
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chromosome-linked mental retardation (Plenge et al. 2002). Thus, to understand 
the etiology of CDKL5-linked disease, determining the characteristics of the 
heterozygous female Cdkl5 KO mice that reproduce the human CDKL5 
deficiency is critical. We found that loss of Cdkl5 in heterozygous female mice 
elicited decreased survival and aberrant dendritic phenotype of newly generated 
granule cells rather similar to homozygous female mice, suggesting that even 
mosaic depletion of Cdkl5 in 50% of the cells in the brain is sufficient to affect 
neuronal survival/differentiation in a more global manner.  
 
 
 
Figure 34 Hypothetical model of CDKL5 function in postnatal 
hippocampus development. 
 
Top: In normal dentate gyrus (DG) primary progenitor cells (type 1) and 
intermediate progenitor cells (IPCs, type 2a/b and type 3 cells) keep 
proliferating, maintaining normal progenitor pool. During postmitotic and 
neuronal differentiation stage, some immature neurons are destined to die, 
while neurons mature to integrate into a functional neural circuit survived.  
 
Bottom: Inactivation of Cdkl5 leads to a hypocellularity and dendritic 
hypotrophy of granule cells in hippocampal dentate gyrus (DG). The 
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numbers of Type 1 and IPCs in theDG were increased, due to the increased 
proliferation rate of these cells. The final neuronal output, however, was 
reduced, due to increase apoptosis of immature neurons, probably due to a 
reduce dendrite development and complexity. 
 
 
5.4. Cdkl5 acts as a pro-survival and pro–differentiative gene by 
modulating Akt/GSK3-β signaling 
 
In order to identify a molecular pathway that could underlie the defective 
neurogenesis in Cdkl5 KO mice, we analyzed the Akt/GSK3-β signaling. 
Glycogen synthase kinase-3 (GSK3-β) is a ubiquitously active serine/threonine 
kinase which is inhibited upon phosphorylation at Ser9 by activated protein kinase 
B (PKB/Akt). Dephosphorylated GSK3-β is a crucial inhibitory regulator of many 
neuronal functions, including neurite outgrowth, synapse formation, neurogenesis 
and survival of newly generated neurons (Cole 2012). We found a deregulation in 
several substrates of the Akt/GSK3-β pathway in Cdkl5 KO mice, suggesting a 
specific alteration of the Akt/GSK3-β pathway in the absence of Cdkl5 that may 
underlie the developmental defects observed. 
Akt/GSK3-β signaling regulates diverse developmental events in the brain, 
including neurogenesis, survival and differentiation. Several studies suggest that 
Akt/GSK3-β signalling plays a role in the death/survival of neural precursors or 
immature neurons. For example, the activation of GSK3-β promotes apoptotic 
signaling in cultured neural precursor cells (NPCs) derived from embryonic 
mouse brains (Eom et al. 2007). GSK3-β also regulates the maturation and neurite 
outgrowth in neurons. Neuronal overexpression of a constitutively active GSK3-β 
causes a delayed postnatal maturation and differentiation of neurons in the mouse 
brain (Spittaels et al. 2000; Spittaels et al. 2002).  
 
The results presented in this study suggest that loss of Cdkl5 impairs 
neural precursor survival and maturation within the DG of the hippocampus, 
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probably by disrupting the Akt/GSK3-β signaling pathway of neuroblasts. Given 
that Akt/GSK3-β signaling is a known regulator of cell proliferation, survival, and 
neural differentiation (Luo 2012), one consequence of reduced Akt/GSK3-β 
activity in the absence of Cdkl5 is the disruption of neuronal development. We 
found that re-expression of CDKL5 in NPCs from Cdkl5 KO mice recovers 
Akt/GSK3-β signaling in parallel to NPCs proliferation/survival and 
differentiation. Similarly, lithium treatments that increase the inhibitory 
phosphorylation of GSK3-β, leading to GSK3-β suppression, result in a fully 
recover of neuronal precursor survival and maturation. These results support the 
view that CDKL5 can function as a pro-survival and -differentiative gene by 
modulating the Akt/GSK3-β signaling.  
 
Although these signaling changes may be indirect effects of Cdkl5 loss-of-
function, these data suggest that CDKL5 plays a critical role in coordinating 
multiple signaling cascades downstream to Akt. Together, these data suggest a 
mechanism by which CDKL5 regulates Akt mediated cellular development, thus 
implicating the Akt pathways as a potential therapeutic target for treatment of 
patients with CDKL5-related disorders. 
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6.CONCLUSIONS 
 
Taken together, our data suggest that CDKL5 modulates the intricate 
balance between precursor proliferation, survival and differentiation by 
contributing to the proper execution of differentiation program. A possible 
mechanism of action of CDKL5 on postnatal development in the DG is illustrated 
(Fig. 34). We suggest that loss of Cdkl5 impairs neurogenic capacity within the 
hippocampal DG, disrupting the Akt/GSK3-β signaling pathway of neuroblasts. 
Since it has been proposed that these regions are involved in memory retrieval 
(Moser and Moser 1998; Greicius et al. 2003), it would be reasonable to 
hypothesize that the mechanisms described could lead to memory loss and thereby 
to cognitive impairment, in CDKL5-related disease patients. 
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